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Automated Glycan Assembly (AGA) is introduced in chapther 1. AGA is a powerful 
technique for the solid-phase synthesis of oligosaccharides. These glycans have potential as 
analytical standards and as substrates for structural and functional analysis of different 
carbohydrate-degrading enzymes. AGA is based on the addition of different building blocks 
(BB) to a functionalized solid support; oligosaccharides of different lengths and branching 
patterns can be produced after iterative cycles of AGA. In chapter 2 AGA was employed to 
prepare the core structure of arabinomannosides (AM) from M. tuberculosis, containing α-
(1,6)-Man, α-(1,5)-Ara and α-(1,2)-Man linkages. The introduction of a capping step after each 
glycosylation and further optimized reaction conditions (time and temperature) allowed for the 
synthesis of a series of oligosaccharides, ranging from hexa- to branched dodecasaccharides. 
These improvements towards a more robust AGA platform ensure high coupling efficiencies 
over long sequences. In a collaboration work with Dr. Abragam, the limits of AGA were 
surpassed, granting access to a 100-mer α-(1,6) polymannoside. The flexibility of AGA in the 
synthesis of long structures was demonstrated by the convergent block coupling. A set of 
oligosaccharide fragments prepared by AGA gave a multiple-branched 151-mer 
polymannoside, the largest polysaccharide prepared by any synthetic method to date. This 
collection of arabinomannosides was used as standards for the developing of a new analytical 
technique, namely, direct imaging of single glycan molecules with sub-nanometer resolution 
using scanning tunneling microscopy (STM). In collaboration with Dr. Xu Wu, direct 
visualization of mannosides at sub-nanometer resolution permitted the differentiation of α-(1,2) 
and α-(1,6) linkages together with the localization of the branching point at a single-molecule 
scale. This technique is expected to be useful for the identification of recurrent structural 
features of glycans with biological importance. 
In Chapter 3 AGA was employed to synthesize a collection of six linear α-(1,6)-
mannosides and seven β-(1,3)-glucans with specific β-(1,6) and β-(1,4) substitution patterns 
containing a free reducing end, using two different traceless photolabile linkers. These 
compounds were used to characterize carbohydrate-degrading enzymes obtained from marine 
sources. Synthetic α-(1,6)-mannosides permitted the characterization of the putative mannanase 
GH76A from Salegentibacter sp.. In collaboration with Dr. Solanki, a detailed 3D structure of 
the active site of GH76A was obtained after the co-crystallization of synthetic mannose tetramer 
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with mutant mannanase GH76. Incubation of these synthetic α-(1,6)-mannosides with GH76A 









Die automatisierte Oligosaccharidsynthese (AGA) ist eine leistungsstarke Technik für die 
Festphasensynthese von Oligosacchariden. Diese Glykane können als analytische Standards 
und als Substrate für die strukturelle und funktionelle Analyse von verschiedenen 
Kohlenhydrat-abbauenden Enzymen dienen. AGA basiert auf der Verknüpfung von 
verschiedenen Bausteinen (BB) an eine funktionalisierte Festphase; Oligosaccharide von 
verschiedenen Längen und Verzweigungen können durch iterative AGA Zyklen produziert 
werden. In Kapitel 2 wurde AGA angewendet, um die Kernstruktur von Arabinomannosiden 
(AM) aus M. tuberculosis herzustellen, die α-(1,6)-Man-, α-(1,5)-Ara- und α-(1,2)-Man-
Verknüpfungen enthalten. Die Verwendung eines Capping-Schrittes nach jeder Glykosylierung 
und zusätzlich optimierte Reaktionsbedingungen (Zeit und Temperatur) haben die Synthese 
von einer Reihe von Oligosacchariden ermöglicht, die von Hexa- bis hin zu verzweigten 
Dodecasacchariden reichen. Diese Steigerung hin zu einer robusteren AGA-Plattform 
gewährleistet hoch effiziente Verknüpfungsschritte über lange Sequenzen. In Zusammenarbeit 
mit Dr. Abragam wurden die Grenzen der AGA übertroffen, wodurch der Zugang zu einem 
100-mer α-(1,6) Polymannosid möglich wurde. Die Flexibilität der AGA in der Synthese von 
langen Strukturen wurde durch konvergente Synthese durch Blockverknüpfungen demonstriert. 
Ein Set von Oligosaccharid Fragmenten, welches mittels AGA hergestellt wurde, ergab ein 
mehrfach verzweigtes 151-mer Polymannosid, welches das bis heute größte Polysaccharid ist, 
das durch synthetische Methoden hergestellt wurde. Diese Bibliothek von Arabinomannosiden 
wurde als Standards für die Entwicklung von einer neuen analytischen Methode verwendet, 
nämlich der Bildgebung von einzelnen Glykanmolekülen mit sub-nanometer Auflösung durch 
die Verwendung von Rastertunnelmikroskopie (RTM, engl. STM). In Kollaboration mit Dr. Xu 
Wu war die direkte Visualisierung von Mannosiden in sub-nanometer Auflösung möglich und 
dadurch die Unterscheidung von α-(1,2)- und α-(1,6)-Verknüpfungen und die Lokalisation der 
Verzweigungen auf der Skala von einzelnen Molekülen. Diese Technik kann dafür benutzt 
werden, wiederkehrende strukturelle Merkmale von Glykanen zu identifizieren, die eine 
biologische Bedeutung haben. 
In Kapitel 3 wurde die AGA verwendet, um eine Sammlung herzustellen, die sechs lineare 
α-(1,6)-Mannoside und sieben β-(1,3)-Glukane mit spezifischen β-(1,6) β-(1,4)-
Substitutionsmustern mit einem freien reduzierenden Ende umfasst. Dafür wurden zwei 
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verschiedene photolabile Linker eingesetzt. Diese Verbindungen fanden Anwendung in der 
Charakterisierung von Kohlenhydrat-abbauenden Enzymen aus dem Meer. Synthetische α-
(1,6)-Mannoside erlaubten die Charakterisierung der vermeintlichen Mannanase GH76A aus 
Salegentibacter sp.. In Kollaboration mit Dr. Solanki konnte nach Co-Kristallisierung des 
synthetischen Mannose Tetramers mit einer mutierten mannanase GH76 eine detaillierte 3D 
Struktur vom aktiven Zentrum von GH76A erhalten werden. Durch Inkubation der 
synthetischen α-(1,6)-Mannoside mit GH67A wurden hydrolysierte Glykane generiert, was 
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This chapter has been modified in part from the following article: 
Pardo-Vargas A, Delbianco M, Seeberger PH: Automated glycan assembly as an 
enabling technology. Current Opinion in Chemical Biology 2018, 46:48-55. DOI: 
10.1016/j.cbpa.2018.04.007 
Carbohydrates are the most abundant biopolymers on earth.1,2 Early perceptions propose 
glycan functions barely as structural support and energy reservoirs; however current studies 
reveal many critical functions of glycans regarding cell-glycans interactions3 and their roles as 
regulatory switches,4,5 cell-cell communication,6 host-pathogen interactions,7 among many 
others. Human cells are covered with glycans, many are found conjugated to proteins and lipids1 
with N- glycosylated and O- glycosylated proteins, the most well-studied. N- and O- glycosyl 
modifications affect the structure, function and stability of the protein. For example, N-glycan 
sites promote proper folding of newly synthesized polypeptides in the endoplasmatic reticulum 
(ER).8 O-glycosylations in mucins act as lubricants in mucus.9 Mixed N- and O-glycans are 
crucial to oocyte fertilization and embryogenesis development.10  
 





Glycolipids such as glycosylphosphatidylinositol (GPI) connect glycoproteins to 
membrane lipids and are involved in membrane trafficking.11 Human blood group antigens are 
determined by small changes on the surface glycans of red blood cells (Figure 1.1).1 
Deep and precise knowledge of the glycans biological functions is crucial for the 
development of pharmacological agents, such as the discovery of bacterial vaccines. Bacteria 
are covered by a dense outer layer of glycans called capsular polysaccharides (CPS).12 CPS 
provide bacteria with a physical barrier for protection. Inducing an immune response against 
those specific bacterial glycans, e.g. CPS from S. pneumonia led to the development of 
Pneumovax® 23 and Prevnar®13 vaccines.13,14 Current efforts to improve the vaccine include 
the incorporation of more S. pneumonia serotypes either via semisynthetic or fully synthetic 
routes.15,16 Anticancer vaccines based on glycans are isolated under development after the 
discovery of tumor-associated carbohydrate antigens (TACAs) from many different forms of 
cancer like breast, colon, and lung. TACAs are glycans markers associated with cancer level of 
invasion and metastasis due to glycosylation changes in N-linked and O-linked glycans.17-20 An 
anticancer vaccine including Globo H antigen, (Figure 1.2) targets CD1d receptors on the 
dendritic and NKT cell surfaces and is currently under clinical phase III studies against prostate 
and breast cancer.21 Glycans can be used to boost the immune response in vaccines, for instance, 
the compound galactolipid KRN700022 (Figure 1.2) and they have been used as an adjuvant 
and an immune stimulator to boost the efficacy of the Globo H vaccine.23 
Glycans have also been modified to generate synthetic drugs called glycomimetic. For 
example, Glucose glycomimetic 2-[18F]Fluoro-2-deoxyglucose (18F-FDG)24 is transported into 
cells, where it accumulates as FDG-6-phosphate. The molecule acts as an indicator of glucose 
uptake, metabolism, and cell viability, for oncology PET imaging. Inhibitors of α-glucosidase 
like Glucobay, which decreases absorption of glucose is used for the treatment of type 2 
diabetes mellitus.25 Heparin glycomimetic Arixtra containing low molecular weight heparin and 
heparin sulfate serves as anticoagulants. The molecule binds to the anti-coagulant factor 
antithrombin (AT),26 which inactivates several enzymes of the coagulation system, and now it 









Figure 1.2 Glycan with relevant pharmacological activity.  
 Challenges in Carbohydrate Syntheses 
Other biopolymers such as oligonucleotides (DNA and RNA) and proteins are well 
understood at the molecular level. For these biopolymers, automated sequencing and synthesis 
have fueled rapid progress in the development of molecular biology tools. The easy 
manipulation of polynucleotides in concert with gene expression technologies made pure 
proteins accessible, thereby advancing proteomics and genomics. 27 In contrast, knowledge of 
oligosaccharides in research fields such as molecular glycobiology is still in its infancy, in part, 
due to the inherent complexity of glycoproteins present in a single cell. Each protein can be 
glycosylated, often in multiple sites.  Furthermore, a new stereogenic center is formed with each 
glycosidic linkage, creating a virtually endless number of possible structures. 
 The great glycan diversity makes purification from natural sources extremely challenging 
and not always feasible.1 Hence access to structurally diverse and complex carbohydrate 
structures is either achieved by chemical or enzymatic synthesis. Enzymatic synthesis 
preparation of polysaccharides using glycosyltransferases or glycosynthases give high yields, 
with high regio- and stereo-specificity without the use of any protecting groups.29 However, 
enzymes technology is not widespread and it is limited to some laboratories, further limits its 
flexibility. Thus, chemical synthesis is frequently the only way to obtain pure glycans. The total 
synthesis of glycans is based on the formation of glycosidic linkages and protecting group 
manipulations.30 The synthetic chemical knowledge has improved to the point, where complex 




but labor-intensive process often becomes a research project itself, since the overall synthesis 
takes many months or years to complete.31, 32 
 The Glycosylation Reaction  
Complex oligosaccharides are made of monosaccharides, which are connected via 
glycosidic bonds. The precise formation of glycosidic bond is likewise a challenge in chemical 
synthesis since the reaction between a glycosylic donor and the hydroxyl group of the acceptor 
generates an additional stereocenter. The mechanism of a chemical glycosylation reaction is 
shown in Figure 1.3. 
 
Figure 1.3 Mechanism of the glycosylation reaction without participating group (top) and with 
(bottom) a participating group. 
The mechanism of the glycosylation reaction is not fully understood; however, certain 
pathways have been established. It is assumed that the glycosylic donor forms an oxocarbenium 
ion after activation with an electrophilic promoter which leads to irreversible elimination of the 
leaving group.33 Recently, such oxocarbenium ion intermediate has been detected by IR 
spectroscopy under cryogenic conditions (Figure 1.3).34 A new glycosidic bond is formed when 
the oxocarbenium ion is attacked by a hydroxyl group of the glycosylic acceptor. The acceptor 
can approach from either the upper face giving the 1,2-trans product (often β) or from the lower 
face, to give the 1,2-cis product (often α). Side-reactions increase the complexity of the 
glycosylation reaction; glycosylic donors can undergo elimination, hydrolysis, rearrangements, 
or orthoester formation.35 Normally a mixture of both α and β isomers are obtained; however, 
several strategies have been developed to take control over the stereoselectivity. Group 
participation effect can influence the stereoselectivity. High 1,2-trans stereoselectivity is 





Typically, an ester protecting group is installed at C-2, which forms an acyloxonium ion 
complex with C-1. This intermediate blocks the α-face and leaves only the β-face free for the 
following attack of the glycosyl acceptor. As a result, 1,2-trans product is formed with high 
selectivity.33, 36 Other ways to use protecting groups to influence the stereochemistry include 
the use of ester protecting groups at the C-6 position of the donor to remotely hinder the β-face 
through either sterical or electronic interactions.37 This effect favors the attack on the α-face to 
promote the selective formation of 1,2-cis glycosidic bonds. Protecting groups can also lock the 
conformation of the donor and influence the stereochemical outcome of the reaction. For 
example, a 4,6-O-benzylidine ring can lock the conformation of mannoside donors to favor the 
challenging β-cis-mannoside linkage.38 Temperature can influence the stereoselectivity of the 
glycosylation since the α-anomer is thermodynamically favored due to the anomeric effect. The 
anomeric effect stabilizes the axial configuration at C-1, via hyperconjugation between the 
unshared electron pair on the ring oxygen atom and the σ* orbital of the axial C-O bond at cis-
C-1.39 The solvent choice affects the stereoselectivity since glycosylation occurs through 
contact ion pair.40 For example, the use of acetonitrile favors the formation of the β-product, 
since the solvent forms an adduct at the α-face, whereas ethereal solvent such as THF, 
diethylether, and 1,4-dioxane promote the α-product.41,42 
A deep understanding of the glycosylation reaction has led to the successful synthesis of 
many complex oligosaccharides. However, obtaining pure natural and non-natural structures is 
a time-consuming process. Automated methods such as Automated Glycan Assembly (AGA) 
technologies were developed to facilitate reliable access to oligosaccharides, which provides 
users with valuable materials to better understand glycan structure-activity relationship for the 
development of molecular glycobiology and material science. 
 Automated Solution-Phase Methods 
Most solution-based methods, aiming to accelerate the synthetic process by reducing the 
number of purification steps in between, are not fully automated and remain labor-intensive. 
The semi-automated computer-based one-pot synthesis is based on the sequential addition of 
building blocks (BBs) according to the difference in their reactivity as calculated by the 
OptiMer software. 43 (Figure 1.4-A) This conceptually attractive methodology requires many 
different mono-, di- and trisaccharide BBs. Another one-pot method is based on the anodic 
oxidation of the glycosylic donor in the presence of tetrabutylammonium triflate (Bu4NOTf) in 




then added and, upon glycosylation, the oxidation process is repeated. 44 An instrument was 
developed to control temperature, delivery of reagents, and the electrical potential of the 
reaction cell. DFT calculations are performed prior to synthesis to estimate the oxidation 
potentials of the building blocks. Recently, the synthesis of the GPI anchor core trisaccharide45 
and a TMG-chitotriomycin precursor 46 were reported. 
Another method uses a fluorous tag linker that is coupled to the desired glycan to simplify 
purification. After, deprotection and chain elongation, the tagged compound is separated from 
the reaction mixture by fluorous solid-phase extraction (FSPE). (Figure 1.4-B) A robot can 
handle the solutions autonomously.47 Linear and branched β-oligomannosides were synthesized 
using a β-directing C-5 participation strategy.48, 49 Recently, automated fluorous-assisted 
synthesis using hypervalent iodonium as glycosylation promoter at ambient temperatures 
permitted the synthesis of a β(1,6)-glucan tetramer.50 A renewable benzyl-type fluorous tag was 
prepared to reduce costs.51 To date, FSPE technique can be applied only to the synthesis of 
short oligomers. Similar to the fluorous tag methodology, the hydrophobically assisted 
switching phase method (HASP) uses a hydrophobic tag to simplify the separation of the 
desired oligosaccharide from the reaction mixture. This strategy was illustrated in the context 
of a nonamannoside synthesis.52 
 






 Solid-phase Methods 
Glycan solid phase synthesis is based on the peptide solid-phase synthesis principles 
introduced by Merrifield.53 Glycosylation occurs in the interphase between the resin and the 
solution, afterward, the excess of reagents is removed by filtration, facilitating purification of 
the intermediates. Although solid supports were used also in carbohydrate synthesis since 
198554 the first automated solid-phase oligosaccharide synthesis (Automated Glycan 
Assembly- AGA) was reported in 2001 by Seeberger, based on an adapted peptide 
synthesizer.55 The desired oligosaccharide is assembled using repeating cycles of glycosylation, 
capping and deprotection steps on a polystyrene Merrifield resin. Iterations of the homemade 
synthesizer led to the development of the commercial version Glyconeer 2.1™ in 2015.55-57  
 The Linkers 
In AGA the glycan is attached to the solid support via a linker that is cleaved upon 
completion of the assembly, affording the target compound. The linker has to tolerate the 
reaction conditions during the assembly process and permit the easy liberation of the final 
product. Following metathesis labile linker 158 and base-labile linker 2,59 the photocleavable 
linkers were developed for their orthogonality to a wide range of reaction conditions (Figure 
1.5). Photocleavable linkers are stable in both acidic and basic conditions and compatible with 
a wide variety of protecting groups including Nap, Fmoc, Lev, Bn and Bz. Aminoalkyl linker 
3 affords conjugation-ready glycans.60 Traceless linker 4 affords a free reducing end after the 
final deprotection.61,62 The current challenge involves further development of the photocleavage 
efficiency, currently around 60-70%, to improve overall yields for AGA. 
 AGA Coupling Cycle 
The glycosylation reaction is the key step during AGA. A collection of “approved” building 
blocks was developed and many BBs are now commercially available.57 For each BB, key 
reaction parameters, such as activators, reaction temperatures, and equivalents of BB per cycle 
were optimized. To minimize the formation of deletion sequences, a large excess of sugar donor 
(ten equiv. per coupling step over two glycosylation cycles) was traditionally used to drive the 
reaction to completion.57 An optimized reaction temperature and concentration permit the 





Figure 1.5 A) The commercial Glyconeer 2.1™ AGA synthesizer, B) Home-built AGA 
synthesizer, C) Overview of the coupling cycle, D) Linkers used for AGA. 
To further improve the coupling cycle, a capping step was introduced to block any unreacted 
acceptor in less than 30 minutes by acetylation using methanesulfonic acid and acetic 
anhydride.64 Capping is compatible with all the protecting groups used to date, increases the 
isolated yield of the desired compound and facilitates the purification of the reaction mixture 
by reducing the number of side-products. The capping step was tested for the assembly of a 
polymannoside (50-mer) resulting in a four-fold yield increase (20% yield) while reducing the 
amount of building block used by 33%.65 Capping is now incorporated in the standard coupling 
cycle.  
 Synthetic Improvements 
AGA had been mainly used to synthesize trans-glycosidic linkages, where the C-2 
participating protecting group ensures stereoselective couplings. Since stereocontrol during cis-
glycosylations cannot rely on C-2 participation, anomeric mixtures are normally observed. 
Oligosaccharides containing multiple cis-glycosidic linkages can be prepared efficiently by 





protecting groups.37 Nine biologically important structures containing cis-galactosidic and cis-
glucosidic linkages were assembled (Figure 1.6). 
Access to sialylated glycans remains challenging. In particular, glycosylation with N-
acetyl-neuraminic acid (Neu5Ac) results in low yields and anomeric mixtures due to low 
reactivity and lack of stereocontrol. The attempt to produce α-(2,6) and α-(2,3) sialylated 
glycans by AGA using a sialyl-monomer was successful, albeit low yielding.66 A combination 
where the glycan backbone is obtained by AGA and further functionalized with 
sialyltransferase (PmST1) permitted easy access to five (2,3)-sialylated glycans. 67 
Glycosaminoglycans (GAGs) are an important class of negatively charged glycans. Their 
structures are highly sulfated, representing one of the most challenging targets for carbohydrate 
chemists. Chondroitin sulfate GAGs with different sulfation patterns were prepared using a 
glucuronic acid BB and two N-acetyl-galactosamine BBs equipped with two temporary 
protecting groups. The Fmoc group was used for chain elongation and the orthogonal levulinoyl 
(Lev) esters marked the hydroxyl groups for sulfation. Fully protected chondroitin-6-sulfate 
and chondroitin-4-sulfate hexasaccharides were synthesized.60,68 Keratan sulfates (KS) 
containing β-(1-4) galactose, β-(1-3) N-acetyl-galactosamine and different sulfation patterns 
were obtained following a similar approach. Three different temporary protecting groups were 
exploited: Nap and Lev esters for subsequent sulfation and Fmoc for chain elongation. The 
orthogonality of the protecting groups permitted to obtain four differently sulfated KS 
tetrasaccharides from a common tetrasaccharide precursor.69 
Most of the previously described advancements were applied for the synthesis of 
oligosaccharides associated with blood group determinants.70 Those are tumor-associated 
carbohydrate antigens (TACAs) and cancer vaccine candidates, also associated with 
immunodeficiency disorders, atherosclerosis, and Guillain–Barré syndrome. cis-Linkage 
formation, sulfation as well as the use of orthogonal temporary protective groups permitted the 
fast assembly of biologically relevant glycans including Lewis H-type I (3) and II (4) glycans.  
 Instrumentation 
The commercial Glyconeer 2.1™ has been placed in several laboratories around the 
world.56 The combination of this instrument with standardized purifications and quality-control 




cianopyvaloyl (Piv-CN) protecting group into a rhamnose BB was key to the assembly of 16-
mer oligorhamnans on the Glyconeer.73 
 
 
Figure 1.6 Recent AGA milestones include the synthesis of: A) oligosaccharides containing 
multiple cis-glycosidic linkages. B) sulfated GAGs C) sialylated glycans D) polysaccharides. 
. 
Efforts to develop an inexpensive synthesis instrument employed a modified HPLC.39,74 A 
column packed with solid support is used as a reactor. A JandaJel resin functionalized with a 
base labile linker serves as the glycosyl acceptor. HPLC pumps are used to deliver the glycosyl 
donor (glucosyl imidate BB, five to ten equivalents) and the deprotection solution. The 
promotor is delivered through the autosampler. The synthesis is monitored using the integrated 
UV detector set at 254 nm. This simple set up has been limited to the production of a 
pentaglucoside so far. Temperature control throughout the synthesis and delivery lines for 





 Applications of Glycans Assembled by AGA 
 Glycan Arrays 
Glycan arrays are standard tools for the high throughput analysis of protein-carbohydrate 
interactions.75 Antibodies associated with diseases, can be detected in biological samples on 
glycan microarrays.75,76 Access to pure glycans for covalent attachment to a surface of the array 
remains a limiting factor. AGA is the ideal tool to create large collections of related compounds, 
permitting to study glycans with a medicinal chemistry approach. For example, conjugation-
ready linear β-(1,3)- and branched β-(1,3)-β-(1,6)-glucan oligosaccharides were assembled and 
immobilized on microarrays. Incubation with human sera revealed that most individuals create 
antibodies that bind to linear glucan, but not to the non-protective branched analogs.77 In 
another report, synthetic keratan sulfate analogs with different sulfation patterns obtained with 
AGA were printed on microarrays. Specific interaction between the disulfated KS 
tetrasaccharide and the adeno-associated virus AAVrh10 gene-therapy vector was observed.69 
AGA was also used to create glycans for determining the binding epitopes of a large number of 
plant cell-wall glycan-directed monoclonal antibodies (mAbs) using a microarray.78-80 This 
information provided a tool for in situ cell wall labeling studies to gain detailed information on 
cell wall polysaccharides in model organism Brachypodium distachyon.81 The binding 
specificities for 25 mAbs that recognize galactosylated xyloglucans (XG) structures were 
determined using the same approach.82 
 Enzyme Substrate Determination 
The oligosaccharide fragments of plant glycans assembled by AGA were used to 
characterize the enzymes involved in biosynthesis. Plant arabinogalactan, glucan and 
arabinoxylan oligosaccharides were assembled to study the substrate specificity of β(1,4)-
endogalactanases,83 lichenase,84 and to map the active site of GH10 and GH11 xylanases.85 
These findings have implications for the structural analyses of pectic polysaccharides. These 
plants oligosaccharides toolbox is currently applied to the characterization of biosynthetic 
enzymes as well as arabinogalactan- and arabinan-directed antibodies.86 
 Vaccine Development  
Glycoconjugates containing synthetic oligosaccharides attached to a carrier protein are 




oligosaccharides, resembling the capsular polysaccharides from Streptococcus pneumonia ST8, 
assembled with AGA, were combined with the marketed polysaccharide-based pneumococcal 
vaccine Prevnar13® while retaining the immunogenicity of both components.15 Synthetic 
antigens from ST3, prepared by AGA, are tested as vaccine candidates.87 
 Materials Chemistry 
The synthesis of 50-mer oligomannosides, the longest polysaccharides assembled from a 
single monomer, set the stage to use AGA for the investigations of carbohydrates as 
materials.64,65 Well-defined oligo- and polysaccharides, resembling natural as well as unnatural 
structures, are ideal probes for the fundamental study of polysaccharides.63 Molecular dynamics 
simulations suggested that different classes of polysaccharides adopt fundamentally different 
conformations. Single-site substitutions alter such conformations and thus permits tuning the 
shape and properties (i.e. solubility) of such compounds. 
 






Over the past two decades, AGA has evolved from humble beginnings to a reliable 
synthesizer, optimized reaction conditions, and commercially-available building blocks that 
made the rapid synthesis of complex oligosaccharides a reality.56,57 Even though challenging 
cis-linkages and structures such as charged polysaccharides are accessible now, some linkages 
(e.g. β-mannose) as well as the stability of sulfates during the deprotection process, remain 
synthetic bottlenecks. Additionally, as longer polysaccharides can be assembled, new 
challenges arise, such as the formation of insoluble compounds and/or aggregates after global 
deprotection. The detailed structural analysis of defined oligo- and polysaccharides will 
advance the synthesis. Specific substitution aiming to alter the structure and properties of these 
compounds will be systematically studied using AGA. These achievements, together with 
improvements in quality control and purification techniques, will have an enormous impact on 
glycoscience.71 
With an expanding collection of pure and well-defined glycans, it will be possible to shed 
more light on new aspects of glycobiology such as carbohydrate-protein interactions as well as 
to stimulate the development and characterization of new enzymes and antibodies. Diagnostic 
and vaccine discovery are being enabled by AGA. Multivalent systems, so far limited to simple 
mono- or disaccharides,88 can now benefit from AGA to use more complex structures to 
resemble the biological environment. AGA will grant access to new carbohydrate-based 
materials for probing fundamental information on polysaccharides. The envisage of unnatural 
compounds such as DNA and peptide conjugates with tuned properties. With AGA 
technologies available as for DNA and peptides, we expect new possibilities and applications 
for carbohydrates.  
 Aim of the Thesis 
The thesis aims to continue the development of a robust and reliable automated platform 
general for glycan synthesis through improved methodologies to obtain glycan libraries, which 
provide valuable materials to understand the functions and the structure of glycans. 
The first objective was to optimize the synthesis of a collection of arabinomannan (AM), 
(Chapter 2.1). For this purpose, a collection of AM oligosaccharides from the Mycobacterium 
tuberculosis was synthesized. The introduction of a capping step after each glycosylation and 




in a faster and more efficient way. With an optimized methodology and reliable platform, the 
limits of AGA were pushed towards the longest polysaccharide ever synthesized, the linear 
100-mer polysaccharide. After 188 hours and 201 steps the polymannoside was obtained with 
99% average yield (Chapter 2.4). Convergent block coupling allowed going even longer, using 
oligosaccharide fragments (30- and 31-mers) prepared by AGA, a branched 151-mer 
polysaccharide was obtained, proving AGA as a solid and mature platform to obtain complex 
molecules. This collection of arabinomannosides were used as standards for the developing of 
a new analytical technique, namely, direct imaging of single glycan molecules with sub-
nanometer resolution using scanning tunneling microscopy (STM). In collaboration with Dr. 
Xu Wu. Direct visualization of mannosides at subnanometer resolution permitted the 
differentiation of α-(1,2) and α-(1,6) linkages together with the localization of the branching 
point at a single-molecule scale. This technique is expected to be useful for the identification 
of recurrent structural features of glycans with biological importance. 
The final objective (chapter 3) was to assemble a collection linear α-(1,6)-mannosides and 
β-(1,3)-glucans with specific β-(1,6)- and β-(1,4)-linkages. These compounds were used to 
characterize carbohydrate-degrading enzymes obtained from marine sources. Synthetic α-(1,6)-
mannosides permitted the characterization of the putative mannanase GH76A from 
Salegentibacter sp.. In collaboration with Dr. Solanki, a detailed 3D structure of the active site 
of GH76A was obtained after the co-crystallization of synthetic mannose tetramer with mutant 
mannanase GH76. Incubation of these synthetic α-(1,6)-mannosides with GH76A generated 












2. Pushing the limits of AGA 
 
This chapter has been modified in part from the following article: 
 
Pardo-Vargas A., Bharate P., Delbianco M., Seeberger P.H. Automated Glycan Assembly 
of Arabinomannan Oligosaccharides from Mycobacterium tuberculosis. Beilstein Journal 
of Organic Chemistry, 2019, 15, 2936-2940. DOI: 10.3762/bjoc.15.288 
 
 Abstract 
Automated Glycan Assembly (AGA) was employed to prepare the core structure of 
arabinomannosides (AM) from M. tuberculosis, containing α-(1,6)-Man, α-(1,5)-Ara and α-
(1,2)-Man linkages. The introduction of a capping step after each glycosylation and further 
optimized reaction conditions (time and temperature) allowed for the synthesis of a series of 
oligosaccharides, ranging from hexa- to branched dodecasaccharides. These improvements 
towards a more robust AGA platform ensure high coupling efficiencies and granted access to a 
100-mer polysaccharide. Using a different strategy namely convergent block coupling a set of 
oligosaccharide fragments prepared by AGA, yielded a multiple-branched 151-mer 
polymannoside, the largest polysaccharide prepared by any synthetic method to date. This 
collection of arabinomannosides represents valuable analytical standards for the developing 
analytical techniques like direct imaging of single glycan molecules with sub-nanometer 
resolution using scanning tunneling microscopy (STM).  
 Optimizing the assembly of Arabinomannan from M. tuberculosis 
Bacterial infections caused by Mycobacterium Tuberculosis (MTB) killed 1.7 million 
people in 2017. Additionally, more than 10 million new TB cases were reported, with 
multidrug-resistant tuberculosis accounting for almost 10% of registered cases.89 The 
development of novel therapeutic agents and more efficient strategies to detect MTB infections 
at an early stage is essential, as an early diagnosis would help to prevent most deaths from TB.89 
Arabinomannans (AM), one of the main components of the mycobacterial cell wall,90 are 
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composed of α-(1,5), α-(1,3) and β-(1,2) arabinoses and α-(1,6) and α-(1,2) mannosides.91-93 
AM are potential clinical biomarkers for infection94-98 due to their roles in the interaction with 
host cells, interference with macrophage activation, and immunosuppression of T cell 
responses.99,100 Identification of novel anti-TB agents that specifically target arabinomannans 
with high sensitivity are required.101-104 Automated Glycan Assembly (AGA) reduces time and 
effort to access complex glycans105 including linear and branched oligoarabinofuranosides α-
(1,5) and α-(1,3),106 and arabinomannose.107,108  
Here, the optimization of AGA modules is described and exemplified for the synthesis of 
oligosaccharides 10-17 that resemble portions of the M. tuberculosis AM core structure (Figure 
2.1). Just three building blocks 1-3 are required to access all six oligosaccharides ranging from 
hexa- to dodecasaccharides.  
 
Figure 2.1 Schematic representation of AGA for oligomannanosides and oligoarabino-




The automated syntheses of oligomannoside 4-6 and oligoarabinomannosides 7-9 were 
performed on a home-built automated synthesizer using a Merrifield resin functionalized with 
a photocleavable linker as solid support.109 A typical AGA cycle consists of three modules 
(Procedure A- Figure 2.2). The acidic wash module prepares the resin for the glycosylation by 
quenching any remaining base from the previous step (20 min). In the glycosylation module, 
the thioglycoside donor is coupled to the resin upon activation with NIS and TfOH (from -40 
°C to -20 °C). Finally, the deprotection module removes the temporary protecting group such 
as Fmoc/Lev to reveal a free hydroxyl group that allows for further chain elongation in the next 
cycle. Fmoc and Lev were used as orthogonal temporary protecting groups, whereby Fmoc is 
cleaved by piperidine (20% solution in DMF) while Lev is removed using hydrazine acetate. 
Iterative cycles continue until the desired structure is obtained. The oligosaccharide products 
are cleaved from the solid support using a flow UV-photoreactor, followed by purification and 
global deprotection.109  
Linear α-(1,6) hexamannoside 4 was synthesized using six coupling cycles with 6.5 
equivalents of mannose BB 1 (Procedure A) was performed in collaboration with Dr Priya 
Bharate. No deletion sequences were observed, and the crude product was purified using normal 
phase HPLC to obtain hexamannoside 4 in 55% yield, based on resin loading.  
 
 Toward more efficient procedures 
 
The doubly branched hexamannoside 5 was assembled using BB 1 for α-(1,6) linkages and 
BB 2 for the α-(1,6) α-(1,2) branching points. First, the linear α-(1,6) trimannose was 
assembled, followed by deprotection of both Lev and Fmoc to reveal three hydroxyl groups. 
Three sequential glycosylation cycles, using BB 1, afforded compound 5 in 37% yield. The 
chromatographic analysis revealed compound 5 as a major product along with pentamer and 
tetramer deletion sequences. To improve the glycosylation efficiency, a new glycosylation 
module, employing higher incubation and reaction temperatures (from -20 °C to 0 °C), was 
introduced (Procedure B) (Figure 2.2). In addition, a capping step after each glycosylation was 
introduced to prevent the formation of undesired side-products.110 These two modifications 
improved the isolated yield of 5 to 53% with no detectable deletion sequences.  






 Module Conditions 
 A: Resin Preparation for Synthesis   
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -40  °C for 5 min, -20  °C for 30 
min 
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B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -40 °C for 5 min, -20 °C for 30 min 
 F: Lev Deprotection 
B: Acidic Wash with TMSOTf Solution 
3x C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
 
BB1 13 eq, -40 °C for 5 min, -20 °C for 30 min 
Procedure B 
 Module Conditions 
 A: Resin Preparation for Synthesis   
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 




B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 




E: Lev Deprotection 
B: Acidic Wash with TMSOTf Solution 
3x C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 20 min 
Figure 2.2 AGA of arabinomannoside 5 using standard procedure A (37% yield) and optimized 








The inclusion of a capping step in the AGA synthesis cycle (Procedure B) was further 
illustrated for the synthesis of oligosaccharide 6-9. AGA of the branched 12-mer mannoside 6 
showed a dramatic improvement, with yields rising from 6% (Procedure A) to 48% (Procedure 
B). Syntheses of linear octamer-arabinomannanoside 7 and linear 12-mer 8, was addressed 
using BB 1 and arabinose BB 3 for the α-(1,5)-Ara linkage. Procedure A efficiently provided 
the linear mannose backbone but resulted only in partial glycosylation of arabinose BB 3, thus 
giving the hexamannoside as main product together with multiple side-products missing one or 
more arabinoses. The desired products 6 and 7 were isolated in only 9% and 7% yield, 
respectively. In contrast, when procedure B was employed, most deletion sequences were 
absent and 6 and 7 were isolated in 56% and 61% yield respectively.  
The advantage of the new procedure became even more apparent for the AGA of 
dodecamer 9, which requires all three BBs. While procedure A afforded dodecamer 9 only in a 




Figure 2.3 ELSD trace of crude-normal phase HPLC of dodecamer 9 obtained with either AGA 
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Compound Procedure A Procedure B 
4 55% - 
5 37% 53% 
6 6% 48% 
7 9% 56% 
8 7% 61% 
9 3% 26% 
Table 2.1 AGA of arabinomannosides 4-9. Procedure A modules: i) Acidic wash ii) 
Glycosylation (from -40 °C to -20 °C) and iii) Fmoc/Lev deprotection.  Procedure B modules: 
i) Acidic wash, ii) Glycosylation (from -20°C to 0 °C) iii) Capping, and iv) Fmoc/Lev 
deprotection. 
The global deprotection of oligosaccharides 4-9 was achieved by removal of the benzoate 
ester protecting groups using Zemplén methanolysis, followed by Pd/C catalyzed 
hydrogenolysis of the carboxybenzyl group and the benzyl ethers. Mannosides 4-6 were 
deprotected and purified using reverse-phase HPLC to obtain fully deprotected mannosides 10-
12. For the arabinomannanosides 7-9, the acid-labile arabinose chain was cleaved during 
hydrogenation (Figure 2.4). To overcome this problem, hydrogenolysis with Pd(OH)2 was 
performed to access the fully deprotected arabinomanosides 13-15. 
 
Figure 2.4 MALDI spectra of AM 8 after acidic hydrogenolysis with Pd/C. Partially cleaved 




Standard post-synthesizer manipulations include photocleavage, global deprotection 
(methanolysis and hydrogenolysis), and two purifications steps, at the protected and at the 
deprotected stage. To simplify this sequence, on resin methanolysis and only one purification 
was attempted and exemplified with the synthesis of the linear pentamannoside 16 and branched 
17. After AGA, the resin was stirred overnight in a basic solution of MeONa in DCM:MeOH, 
followed by photocleavage of the polymannoside from the resin. Complete deprotection of 
benzoyl groups was confirmed using MALDI. Afterwards, benzyl ethers were removed by 
hydrogenolysis with Pd/C followed by RP-HPLC purification. For linear pentamannoside 16 
42% yield was obtained based on resin loading. Likewise, for branched mannoside 17, this 
protocol yielded 11%. Both 16 and 17 were obtained in a fast and efficient way avoiding a 
purification step with comparable yields over the traditional 2 steps purification.  
With these optimized conditions, a total of eight AM oligosaccharides containing α-(1,6)-
Man, α-(1,5)-Ara and α-(1,2)-Man were synthesized by automated glycan assembly, using three 
monosaccharide building blocks (Figure 2.5). 
Figure 2.5 Schematic representation of LM and AM oligomers using AGA.  
 Pushing the limits: Towards the total synthesis of polysaccharides 
AGA is a highly efficient platform for the synthesis of long polysaccharides, with an 
average yield of 98.5% for every coupling step.110,111 Since efficiency sets the size limit of the 
molecule that can be prepared without intermediate purification, this work plans to push the 
limits of AGA towards the longest oligosaccharide ever synthesized by any synthetic method. 
Polymannosides were chosen to illustrate the concept as they do not form rigid tertiary 
structures that complicate the assembly of cellulose and chitin oligomers.113 For AGA the 
previous limit was reached at 50-mer polysaccharides.110,111 Using the optimized procedure B 
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(Section 2.3), the synthesis of a 100-mer polymannoside 18, the largest polysaccharide, was 
pursued in collaboration with Dr. Joseph Abragam (Figure 2.6). 
.  
      
Figure 2.6 AGA of protected 100-mer α-(1,6)-polymannoside 18 followed by photo-cleavage 
and two steps global deprotection yielded 100-mer α-(1,6)-polymannoside 20.  
 
Standard Merrifield resin equipped with a photo-cleavable linker and mannose 
thioglycoside BB 1 was employed on 19 µmol scale using a four-steps cycle (Procedure B). 
After every twenty or thirty coupling cycles, ten beads of resin were removed from the reaction 
vessel and the product was cleaved and analyzed by HPLC and MALDI to ascertain synthesis 
success. At the 40-mer stage, the glycosylation time was doubled from 20 to 40 min to ensure 
quantitative reactions as failure sequences were increasingly detected in the crude products. At 
the 70-mer stage, following the reaction progress became extremely challenging since no 
ionization was observed in MALDI using 2,5-dihydroxybenzoic acid (DHB) as a matrix. A 
different matrix based on 2′,4′,6′-Trihydroxyacetophenone (THAP) was used to overcome the 
challenge since it is less prone to fragment glycans. Beyond the 80-mer stage, all glycosylations 
were allowed to proceed for 60 min to ensure the highest possible yields. 
 
Figure 2.7 Crude HPLC of 100-mer 18 (tR 17.8 min) and main side-product 100-mer 19 (tR 





After 188 hours and 100 coupling cycles, 9 g of building block 1 were consumed to obtain 
100-mer 18 in a 5% yield (Figure 2.7) after photo-cleavage and HPLC purification. As main 
side-product, compound 19 was identified as a 100-mer missing three benzyl ether protective 
groups, lost during photochemical release from the resin. To avoid this side reaction, the 
photocleavage setup was revisited. The mercury lamp with a 280 nm filter used to photocleave 
the resin was replaced by a 365 nm UV lamp. However, after 30 min of irradiation time, the 
amount of the side-product 19 increased. For future experiments deprotection of long 
polysaccharides, it is recommended to reduce the irradiation time.  
 Cleavage of all ester protective groups by treatment with sodium methoxide, followed by 
palladium-catalyzed hydrogenation under pressure for 72 h to release all benzyl ether protective 
groups yielded the 100-mer polymannoside 20. The compound was purified with reversed 
phase HPLC. 100-mer polymannoside 20 was characterized by 1H-and 13C-NMR as well as 
MALDI analysis. To assure that 19 was, in fact, the 100-mer missing three benzyl groups, the 
same two steps deprotection used for 18 were performed. MALDI, NMR and chromatographic 
data unequivocally identify 20 as the product of deprotection of 19.  
AGA of 20 the largest polysaccharide assembled to date illustrates the efficiency, and 
reliability of this platform. AGA maintained for 188 hours an average yield of 98.5% per step 
after 200 synthetic steps. To demonstrate that AGA is not only a reliable but also flexible 
platform, a branched and longer structure will be synthesized using a block coupling strategy.  
 Convergent 31+30+30+30+30 block coupling  
Block couplings of polysaccharides prepared by AGA could give raise to even larger and 
more complex polysaccharides. Two polysaccharide blocks, a linear 30-mer α-(1,6) 
polymannoside 23 and branched 31-mer polymannoside 24, unified in a 31+30+30+30+30 
coupling, will create branched 151-mer 25 (Figure 2.8).  
  




Figure 2.8 Schematic representation of convergent 31+30+30+30+30 block coupling for 
synthesis branched 151-mer.  
To synthesize the fluoride donor 23,  a recently developed traceless photocleavable linker 
21 based on the o-nitrobenzyl scaffold was used (Figure 2.9).114 This linker, upon photo-
cleavage, reveals an oligosaccharide with a free reducing end that can be further functionalized 
to obtain a glycosyl donor or deprotected to obtain fully natural glycans. 
 
Figure 2.9 Photocleavable linkers attached to a Merrifield resin A., After photocleavage 
standard resin reveals a Cbz protected amino-n-pentanol linker (in red) B, Photocleavage of 21 
will reveal the product with a free reducing end. 
 After thirty AGA cycles with BB 1 the partially protected 30-mer 22 was obtained in 30% 
yield. Synthesis of the donor was performed by Dr. Abragam fluoride donor 23 in 90% yield 
by treatment of 22 with deoxo-fluor. (Figure 2.10) 




Branched 31-mer polymannoside 24 (Figure 2.11) that will serve as acceptor in the 
subsequent block coupling was prepared by AGA using α-(1,6) mannose BB 1 and mannose 
BB 2 for the branching positions. Merrifield resin equipped with standard amine linker at the 
reducing end was used to prepare 31-mer 24. After incorporating four times mannose 
thioglycoside BB 1 (6.5 eq), branching BB 2 followed. The first two parallel couplings with 
BB 1 required ten equivalents to glycosylate the secondary C2-hydroxyl group and install an α-
(1,2) linkage. After the next three parallel glycosylations with BB 1, this process was repeated 
following incorporation of two further branching points with BB 2, in order to rapidly grow 31-
mer polymannoside. Photo-cleavage and subsequent purification yielded 30 mg of 31-mer 
polymannoside acceptor 24 (Figure 2.11).   
 
Figure 2.11 AGA of 31-mer polymannoside acceptor 24.  
Dr. Abragam optimized the block coupling conditions to connect four units of 30-mer 
glycosyl fluoride 23 and 31-mer acceptor 24. Six equivalents of 23 in the presence of a silver 
perchlorate as a promotor. These activation conditions completed the glycosylation without the 
formation of significant amounts of side-products in just 30 minutes affording the desired 151-
mer 25 in a 78% yield. 
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Figure 2.12 30-mer donor 23 and branched 31-mer acceptor 24 yielded 78% of fully protected 
151-mer 25. 
Purification of 25 was challenging since the products diffuses throughout the elution run 
(Figure 2.12). This could be ascribed to the size of 25 that is in fact bigger than the pore size of 
the diol column employed (300 Å). However, after three purifications by normal-phase HPLC, 
the desired 151-mer product 25 was separated from the 121-mer side-product and isolated in a 
78% yield.  
 
Figure 2.12 HPLC trace of 25 after one NP purification. Two more sequential HPLC run were 
needed to obtain pure 151-mer. Both compounds diffused throughout the elution run. 
To remove 302 benzyl ethers protective groups, 144 benzoate and four acetate esters as 
well as one Cbz amine protective group, fully protected 151-mer 25 was treated with sodium 




of palladium on carbon under hydrogen pressure for 60 h to cleave all benzyl ethers and the 
Cbz group.  
Standard purification methods including C-18 RP column and Hypercarb column resulted 
in mixtures of 26 with side-products of incomplete deprotection. Size exclusion 
chromatography using a TSKgel G3000 PWXL column with water as eluent, furnished fully 
deprotected 151-mer 26 in 41% yield. Analysis by 1H-, and 13C-NMR as well as MALDI-mass 
spectrometry unequivocally ascertained the synthesis of branched 151-mer 26 as the largest 
synthetic polysaccharide to date (Figure 2.13).  
 
Figure 2.13 Linear 100-mer 19 and branched 151-mer 26. 
 
 Perspectives of AGA as source of materials for structural analysis 
AGA offers a fast and efficient platform to obtain oligo- and polysaccharides with defined 
substitution patterns to systematically study the structure of glycans. These collections of 
related compounds offer the perfect substrate for the development of new structure sensitive 
methods. Traditional analytical methods like NMR analysis of long polysaccharides are 
complex, and so far, the detailed structural analysis of glycans has been ignored. Nonetheless, 
new analytical methods have been developed using oligosaccharides produced by AGA as 
standards to obtain detailed structural information, for instance, ion mobility- mass 
spectrometry (IM-MS)117 have permitted to unambiguously identify regio-  and stereoisomers. 
Other analytical techniques like cryo-IR118 spectroscopy coupled to mass selectors give 
fingerprints of intact glycans and their fragment ions may eventually enable the reliable 
identification of any given glycan.118,119 AGA offered analytical standards to exploit the full 
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potential of these new emerging analytical techniques. Here, it is presented a new method for 
structural analysis by direct imaging of single glycan molecules with sub-nanometer resolution 
using scanning tunneling microscopy (STM) and oligosaccharides produced by AGA as 
reference compounds. 
 Single Glycan Imaging 
In collaboration with the Max Planck Institute for Solid State Research, we developed a 
method to directly visualize single glycan molecules through the combination of ion beam 
deposition and scanning tunneling microscopy (STM) in ultra-high vacuum (UHV), Glycan 
samples are prepared via electrospray ion beam deposition (ES-IBD).A molecular ion beam of 
intact, non-volatile glycans (Figure 2.14a)is purified by a mass-to-charge ratio (m/z), filter, and 
monitored by time-of-flight mass spectrometry before its gentle deposition onto the atomically 
clean Cu(100) surface in UHV.120,121 Only a minute amount of sample, in the range of 
microgram, is needed for a series of experiments (by Dr Xu Wu).  
 
 
Figure 2.14 STM image of the linear mannoside 16 a, Schematic workflow of glycan transfer, 
purification and deposition via ES-IBD combined with mass selection and single glycan STM 
imaging in UHV. c, STM image of α-(1,6) pentamannoside 16 showing a protrusion for every 




Pure oligosaccharides with defined sequence and connectivity were prepared by AGA122 
as mentioned in section 2.3 and deposited on the surface as negatively charged glycans by ES-
IBD. Single-molecule deposition is obtained by suppressing molecular surface diffusion that 
leads to agglomeration by maintaining the sample in ultra-high vacuum at 120 ºK during 
deposition and transfer, and at 4 ºK for imaging. Single molecule preparation allows for detailed 
structural inspection and comparison of different oligosaccharide sequences. 
 α-(1,6) Pentamannoside 16 containing an alkylamino linker group at the reducing end, was 
used for initial imaging experiments. Single monosaccharide subunits are resolved as five 
protrusions (Figure 2.14d). The heights of each monosaccharide vary between 0.15 and 0.25 
nm, often clearly separated from each other by local minima (see the red line profile in Figure 
2.14d). The distance between monosaccharides is 0.51 ± 0.08 nm (peak to peak). The 
alkylamino linker is seen as a low height feature at one end of the molecule, permitting to 
identify the glycan reducing end. Shape, size and spacing of the subunits is consistent with 
recent findings of STM imaging of disaccharides.123 
To explore whether isomers with different connectivity can be distinguished, two branched 
hexamannosides, hexamannoside 11 (Figure 2.15 a) containing two α-(1,2) branching points at 
residues R2 and R3, and hexamannoside 17 (Figure 2.15 d) containing only one α-(1,2) 
branching point at R2 were deposited on the Cu surface and directly imaged. Representative 
STM images reveal structures where branching is clearly visible (Figure2.15). The STM image 
of 11 shows two side chains branching out at nearly a 90° angle to the opposite sides of the 
linear backbone. Three interunit distances of 0.49 ± 0.06 nm are assigned to the α-(1,6) linkage, 
in agreement with the observation for the linear pentamannoside 16. The α-(1,2) linkages appear 
significantly longer (0.62 ± 0.04 nm). The subsequent, unambiguous assignment of the 
complete molecule 11 reveals a bend in the α-(1,6) connected backbone. The interunit distance 
does not represent the exact distances of the glycosidic linkage,123 however, as the distances 
measured were reproduced for several molecules, it is a reliable parameter to distinguish 
between α-(1,2) and α-(1,6) linkages. 





Figure 2.15 STM image of branched hexamanosides a, 11 and d, 17. b, e, Typical STM image 
of the branched hexamannosides 11 and 17 with schematic diagrams of the conformations on 
the top right corner. The scale bar is 1 nm. c, f, Line profile of the molecules showing peaks for 
every monosaccharide unit. The different colored line profiles have an offset of 0.05 nm. The 
inset shows the direction of the line profile. 
The features observed in the STM image of hexamannoside 17 are a result of the greater 
flexibility of this oligosaccharide. The conformational freedom of the longer side branch often 
impedes the direct distinction of the branching point due to 3D folding. The representative STM 
image of 17 (Figure 2.15e) shows a molecule sufficiently spread to allow for the direct 
identification of the branching point. The amino linker identifies residue R1 and thereby the 
position of the branching point related to the overall structure. The increased distance of the α-
(1,2) linked branch allows for the unambiguous assignment of oligosaccharide 17.  
The direct visualization of single glycans at subnanometer resolution opens up new avenues 
for glycan characterization. Single glycans can be imaged and their structure can be 
unambiguously determined. Loss of information due to conformational averaging over time is 
prevented by cryogenic conditions. The tandem approach of preparative mass spectrometry 
with scanning probe microscopy is expected to be useful for the identification of recurrent 





AGA is a technology in constant development. Improvements in hardware, modules and 
conditions over the last two decades made AGA a robust technology. Shorter cycles, the 
introduction of a capping step after each glycosylation, and optimized reaction conditions 
increased the efficiency of every coupling steps and permitted the synthesis of AM 
oligosaccharides containing α-(1,6)-Man, α-(1,5)-Ara and α-(1,2)-Man, using three 
monosaccharide building blocks. AGA of the 100mer, the largest polysaccharide assembled to 
date illustrated the efficiency and reliability of this platform since AGA was consistent over 
201 synthetic steps with an average yield of 98.5% per step. AGA is still in constantly 
developing, and now is more flexible since the introduction of new traceless linker to synthesize 
polysaccharide donors that allowed the assembly of the biggest synthetic polysaccharide to date 
a 151 polymannoside.  
AGA offers a fast and efficient platform to obtain oligo- and polysaccharides with defined 
substitution patterns to systematically study the structure of glycans. Direct visualization of 
single glycans of mannosides at sub-nanometer resolution using STM permitted the 
differentiation of α-(1,2) and α-(1,6) linkages together with the localization of the branching 
point at a single-molecule scale. This opens up new avenues for glycan characterization. Single 
glycans can be imaged and their structure can be unambiguously determined. The tandem 
approach of preparative mass spectrometry with scanning probe microscopy is expected to be 








 General Materials and Methods 
 
All chemicals used were reagent grade and used as supplied unless otherwise noted. All 
building blocks used were purchased from GlycoUniverse, Germany. Automated syntheses 
were performed on a home-built synthesizer developed at the Max Planck Institute of Colloids 
and Interfaces.108 Merrifield resin LL (100-200 mesh, NovabiochemTM) was modified and used 
as solid support.105 Analytical thin-layer chromatography (TLC) was performed on Merck silica 
gel 60 F254 plates (0.25 mm). Compounds were visualized by UV irradiation or dipping the 
plate in a p-anisaldehyde (PAA) solution. Flash column chromatography was carried out by 
using forced flow of the indicated solvent on Fluka Kieselgel 60 M (0.04 – 0.063 mm). Analysis 
and purification by normal and reverse phase HPLC was performed using an Agilent 1200 
series. Products were lyophilized using a Christ Alpha 2-4 LD plus freeze dryer. 1H, 13C and 
HSQC NMR spectra were recorded on a Varian 400-MR (400 MHz), Varian 600-MR (600 
MHz), or Bruker Biospin AVANCE700 (700 MHz) spectrometer. Spectra were recorded in 
CDCl3 by using the solvent residual peak chemical shift as the internal standard (CDCl3: 7.26 
ppm 1H, 77.0 ppm 13C) or in D2O using the solvent as the internal standard in 
1H NMR (D2O: 
4.79 ppm 1H) and a D6-acetone spike as the internal standard in 13C NMR (acetone in D2O: 
30.89 ppm 13C) unless otherwise stated. High resolution mass spectra were obtained using a 
6210 ESI-TOF mass spectrometer (Agilent) and a MALDI-TOF AutoflexTM (Bruker). MALDI 
and ESI mass spectra were run on IonSpec Ultima instruments.  
 Solvents used for dissolving building block and preparing the activator, TMSOTf and 
capping solutions were taken from an anhydrous solvent system (jcmeyer-solvent systems). 
Other solvents used were HPLC grade. The building blocks were co-evaporated three times 
with toluene and dried 2 h under high vacuum before use. Activator, deprotection, acidic wash, 
capping and building block solutions were freshly prepared and kept under argon during the 
automation run. All yields of products obtained by AGA were calculated based on resin loading. 
Resin loading was determined by performing one glycosylation (Module C) with ten 
equivalents of building block followed by DBU promoted Fmoc-cleavage and determination of 




 Preparation of stock solution. 
 
• Building block: building block was dissolved in 1 mL dichloromethane (DCM).  
• Activator solution: 1.56 g of recrystallized NIS was dissolved in 60 mL of a 2:1 
mixture of anhydrous DCM and anhydrous dioxane. Then triflic acid (67 μL) was 
added. The solution is kept at 0 °C for the duration of the automation run. 
• Fmoc deprotection solution: A solution of 20% piperidine in dimethylformamide 
(DMF) (v/v) was prepared. 
• TMSOTf solution: Trimethylsilyl trifluoromethanesulfonate (TMSOTf) (0.9 mL) 
was added to DCM (90 mL). 
• Capping solution: A solution of 10% acetic anhydride (Ac2O) and 2% 
methanesulfunic acid (MsOH) in anhydrous DCM (v/v) was prepared. 
• Lev deprotection solution: Hydrazine Acetate (550 mg) was dissolved in a 
solution of 4:1:0.25 Pyridine:AcOH:H2O (40 mL).   
 
 Modules for automated synthesis 
 
  Module A: Resin Preparation for Synthesis (20 min) 
 
All automated syntheses were performed on 19 µmol scale. Resin was placed in the 
reaction vessel and swollen in DCM for 20 min at room temperature prior to synthesis. During 
this time, all reagent lines required for the synthesis were washed and primed. Before the first 
glycosylation, the resin was washed with the DMF, tetrahydrofuran (THF), and DCM (three 
times each with 2 mL for 25 s). This step is conducted as the first step for every synthesis. 
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 Module B: Acidic Wash with TMSOTf Solution (20 min) 
The resin was swollen in 2 mL DCM and the temperature of the reaction vessel was 
adjusted to -20 °C. Upon reaching the temperature, TMSOTf solution (1 mL) was added drop 
wise to the reaction vessel. After bubbling for 3 min, the acidic solution was drained and the 
resin was washed with 2 mL DCM for 25 s. 
 Module C: Thioglycoside Glycosylation (20-60 min) 
The building block solution (0.150 mmol of BB in 1 mL of DCM per glycosylation) was 
delivered to the reaction vessel. After the set temperature (T1) was reached, the reaction was 
started by drop wise addition of the activator solution (1.0 mL, excess). The glycosylation was 
performed by increasing the temperature to T2 for 20-60 min (depending on oligosaccharide 
length). After completion of the reaction, the solution is drained and the resin was washed with 
DCM, DCM:dioxane (1:2, 3 mL for 20 s) and DCM (twice, each with 2 mL for 25 s). The 
temperature of the reaction vessel is increased to 25 °C for the next module. 
 Module D: Capping (30 min) 
 The resin was washed with DMF (twice with 2 mL for 25 s) and the temperature of the 
reaction vessel was adjusted to 25 °C. Pyridine solution 2 mL (10% in DMF) was delivered into 
the reaction vessel. After 1 min, the reaction solution was drained, and the resin washed with 
DCM (three times with 3 mL for 25 s). The capping solution 4 mL was delivered into the 
reaction vessel. After 20 min, the reaction solution was drained, and the resin washed with 
DCM (three times with 3 mL for 25 s).  
  Module E: Fmoc Deprotection (14 min) 
 The resin was washed with DMF (three times with 2 mL for 25 s) and the temperature of 
the reaction vessel was adjusted to 25 °C. Fmoc deprotection solution (2 mL) was delivered 
into the reaction vessel. After 5 min, the reaction solution was drained, and the resin washed 
with DMF (three times with 3 mL for 25 s) and DCM (five times each with 2 mL for 25 s). The 





 Module F: Lev deprotection (ca. 100 min)  
The resin was washed with DMF (3×30 sec) and 1.3 mL DCM added to the reaction vessel. 
Solution F (0.8 mL) was added to the reaction vessel, and the temperature was adjusted to 25 
°C. After 30 min, the reaction solution was drained, and the entire cycle was repeated twice 
more. After Lev deprotection was complete, the resin was washed with DMF, THF and DCM. 
 Post-synthesizer Manipulations 
 Cleavage from Solid Support 
After automated synthesis, the oligosaccharides were cleaved from the solid support using 
a continuous-flow photo reactor. The Vapourtec E-Series UV-150 Photoreactor Flow 
Chemistry System with mercury lamp was employed. The resin, suspended in CH2Cl2, was 
loaded into a plastic syringe. The suspension was pumped using a syringe pump (PHD2000, 
Harvard Aparatus) at 1 mL/min through a 10 mL reactor, constructed of 1/8 inch o.d. FEP 
tubing. The temperature of the photoreactor was maintained at 20 C.108 
For selected cleavages, the mercury lamp was replaced by a LED 365 nm UV lamp. 
 Oligosaccharide deprotection 
Module G: Methanolysis 
The protected oligosaccharide was dissolved in MeOH:DCM (1.5 mL,1:1). NaOMe in 
MeOH (0.1 mL of 0.5M solution) was added to the solution and stirred at room temperature. 
After 12 h, the solution was neutralized with Amberlite IR-120 (H+ form) resin, filtered and 
concentrated in vacuo. The crude compound was used for hydrogenolysis without further 
purification.  
Module H: Hydrogenolysis with Pd/C 
The crude compound obtained from Module G was dissolved in 2 mL of DCM:tBuOH:H2O 
(1:0.5:0.5) and Pd/C (10%) was added. The reaction was stirred in H2 bomb with 60 psi pressure 
for 16 hours. The reaction was filtered, washed with DCM, tBuOH and H2O. The filtrates were 
concentrated in vacuo.  
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Module I: Hydrogenolysis with Pd(OH)2/C 
The crude compound obtained from Module G was dissolved in 2 mL of EA:tBuOH:H2O 
(1:0.5:0.5) and Pd(OH)2/C was added. The reaction was stirred in H2 bomb with 60 psi pressure 
for 16 hours. The reaction was filtered, washed with EA, tBuOH and H2O. The filtrates were 
concentrated in vacuo. 
 Purification 
Solvent was evaporated in vacuo and the crude products were dissolved in 1:1 mixture of 
hexane and ethyl acetate and analyzed using analytical HPLC (DAD1F, 280 nm). Pure 
compounds were afforded by preparative HPLC (Agilent 1200 Series spectrometer). 
Method A: (YMC-Diol-300 column, 150 x 4.6 mm) flow rate of 1.0 mL / min with Hex – 
20% EtOAc as eluent [isocratic 20% EtOAc (5 min), linear gradient to 55% EtOAc (45 min), 
linear gradient to 100% EtOAc (5 min)]. 
Method B: (YMC-Diol-300 column, 150 x 20 mm) flow rate of 15 mL / min with Hex – 
20% EtOAc as eluent [isocratic 20% EtOAc (5 min), linear gradient to 55% EtOAc (45 min), 
linear gradient to 100% EtOAc (5 min)]. 
Method C: (Synergi Hydro RP18 column, 250 x 4.6 mm) flow rate of 1.0 mL / min with 
H2O (0.1% formic acid) as eluents [isocratic (5 min), linear gradient to 10% ACN (30 min), 
linear gradient to 100% ACN (5 min)]. 
Method D: (Synergi Hydro RP18 column, 250 x 10 mm) flow rate of 4.0 mL / min with 
H2O (0.1% formic acid) as eluents [isocratic (5 min), linear gradient to 10% ACN (30 min), 
linear gradient to 100% ACN (5 min)]. 
Method E: (YMC-Diol-300 column, 150 x 4.6 mm) flow rate of 1.0 mL / min with Hex – 
35% EtOAc as eluents [isocratic 35% EtOAc (5 min), linear gradient to 60% EtOAc (5 min), 
linear gradient to 60% EtOAc (30 min), linear gradient to 100% EtOAc (5 min)]. 
Method F: (YMC-Diol-300 column, 150 x 20 mm) flow rate of 15 mL / min with Hex – 
35% EtOAc as eluents [isocratic 35% EtOAc (5 min), linear gradient to 60% EtOAc (75 min), 




Method G: (YMC-Diol-300 column, 150 x 4.6 mm) flow rate of 1.0 mL / min with Hex – 
40% EtOAc as eluents [isocratic 40% EtOAc (5 min), linear gradient to 70% EtOAc (5 min), 
linear gradient to 70% EtOAc (30 min), linear gradient to 100% EtOAc (5 min)]. 
Method H: (YMC-Diol-300 column, 150 x 20 mm) flow rate of 15 mL / min with Hex – 
40% EtOAc as eluents [isocratic 40% EtOAc (5 min), linear gradient to 70% EtOAc (75 min), 
linear gradient to 100% EtOAc (10 min)]. 
Method I: (TSKgel G 3000 PWXL column, 7.8 mm ID x 30 cm) flow rate of 0.4 mL / min 
with water as eluent. 
Method J: (YMC-Diol-300 column, 150 x 4.6 mm) flow rate of 1.0 mL / min with Hex – 
50% EtOAc as eluents [isocratic 50% EtOAc (5 min), linear gradient to 75% EtOAc (5 min), 
linear gradient to 75% EtOAc (30 min), linear gradient to 100% EtOAc (5 min)]. 
Method K: (YMC-Diol-300 column, 150 x 20 mm) flow rate of 15 mL / min with Hex – 
50% EtOAc as eluents [isocratic 50% EtOAc (5 min), linear gradient to 75% EtOAc (75 min), 
linear gradient to 100% EtOAc (10 min)]. 
Method J: (Hypercarb column, 150 x 4.6 mm) flow rate of 0.7 mL / min with H2O (0.1% 
formic acid) as eluents [isocratic (5 min), linear gradient to 30% ACN (30 min), linear gradient 
to 100% ACN (5 min)]. 
Method K: (Hypercarb column, 150 x 10 mm) flow rate of 1.3 mL / min with H2O (0.1% 
formic acid) as eluents [isocratic (5 min), linear gradient to 30% ACN (30 min), linear gradient 
to 100% ACN (5 min)]. 
Method L: (Synergi Hydro RP18 column, 250 x 4.6 mm) flow rate of 1.0 mL / min with 
H2O (0.1% formic acid) as eluents [isocratic (5 min), linear gradient to 30% ACN (30 min), 
linear gradient to 100% ACN (5 min)]. 
Method M: (Synergi Hydro RP18 column, 250 x 10 mm) flow rate of 4.0 mL / min with 
H2O (0.1% formic acid) as eluents [isocratic (5 min), linear gradient to 30% ACN (30 min), 
linear gradient to 100% ACN (5 min)].  
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 AGA synthesis 
 Synthesis of α-(1,6) linear hexamannoside (4) 
 
Procedure A 
 Module Conditions 
 A: Resin Preparation for Synthesis  
 
6 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation BB1 6.5 eq, -40 °C for 5 min, -20 °C for 30 min 
E: Fmoc Deprotection  
 
Cleavage from the solid support as described in Post-synthesizer manipulations, followed 
by purification using preparative HPLC (Method B) afforded the fully protected hexasaccharide 
4 (20 mg, 55%). 
Crude NP-HPLC of hexasaccharide 4 (ELSD trace, Method A, tR = 25.3 min) 
 
1H NMR (400 MHz, CDCl3) δ
  8.24 – 8.09 (m, 12H), 7.64 (s, 1H), 7.56 – 7.46 (m, 17H), 
7.38 – 7.30 (m, 12H), 7.29 – 7.11 (m, 56H), 5.85 (d, J = 9.0 Hz, 4H), 5.80 (s, 1H), 5.67 (s, 1H), 




– 4.41 (m, 7H), 4.37 (d, J = 12.4 Hz, 2H), 4.14 – 3.86 (m, 13H), 3.84 – 3.59 (m, 11H), 3.58 – 
3.52 (m, 2H), 3.47 (dd, J = 16.9, 9.7 Hz, 4H), 3.22 – 3.16 (m, 2H), 1.64 – 1.56 (m, 2H), 1.55 – 
1.47 (m, 2H), 1.41 – 1.33 (m, 2H); m/z (HRMS+) 2937.160 [M + Na]+ (C175H175NO39Na 
requires 2937.163).Proton signals are in agreement with previous reports by Delbianco et al.63 
 
Deprotection of 4 (as described in Module G and H), followed by purification using 
preparative HPLC (Method L, tR = 22.2 min) afforded compound 10 (3.9 mg, 52%).  
RP-HPLC of purified hexasaccharide 10 (ELSD trace, Method J, tR = 22.2 min) 
 
Analytical data for 10.1H NMR (400 MHz, D2O) δ 4.89 – 4.85 (m, 5H), 4.83 (s, 1H), 3.98 
– 3.95 (m, 5H), 3.94 – 3.88 (m, 7H), 3.85 (s, 1H), 3.84 – 3.82 (m, 5H), 3.80 – 3.77 (m, 5H), 
3.76 – 3.71 (m, 8H), 3.71 (d, J = 2.3 Hz, 2H), 3.69 – 3.60 (m, 4H), 3.57 – 3.51 (m, 1H), 2.98 (t, 
J = 7.6 Hz, 2H), 1.71 – 1.61 (m, 4H), 1.50 – 1.37 (m, 2H); 13C NMR (100 MHz, D2O) δ 99.89, 
99.42, 99.30, 72.73, 70.92, 70.84, 70.80, 70.78, 70.72, 70.69, 70.55, 70.07, 69.98, 69.94, 67.63, 
66.75, 66.61, 66.56, 65.61, 65.58, 65.53, 60.94, 39.38, 28.04, 26.57, 22.53; m/z (HRMS+) 
1076.424 [M + H]+ (C41H73NO31 requires 1076.423). Proton and Carbon signals are in 
concordance as previously reported by Delbianco et al.63 
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 Synthesis of α-(1,6) linear α-(1,2) branched hexamannoside (5) 
 
Procedure A 
 Module Conditions 
 A: Resin Preparation for Synthesis   
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -40 °C for 5 min, -20 °C for 30 min 
 
2       
B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -40 °C for 5 min, -20 °C for 30 min 
 F: Lev Deprotection 
B: Acidic Wash with TMSOTf Solution 
3x C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
 
BB1 13 eq, -40 °C for 5 min, -20 °C for 30 min 
 
Procedure B 
 Module Conditions 
 A: Resin Preparation for Synthesis   
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 20 min 
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 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 




F: Lev Deprotection 
B: Acidic Wash with TMSOTf Solution 
3x C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
 




Cleavage from the solid support as described in Post-synthesizer manipulations followed 
by purification using a preparative HPLC (Method B), to provide the fully protected branched 
hexasaccharide 5. For procedure A: 12.5 mg, 4.62 μmol, 37%, based on resin loading. For 
procedure B: 18.0 mg, 6.65 μmol, 53%, based on resin loading. 
Crude NP-HPLC of hexasaccharide 5. A) Procedure A . B) Procedure B (ELSD trace, 
Method A, tR = 28.5 min) 
  
1H NMR (400 MHz, CDCl3) δ 8.08 – 7.87 (m, 9H), 7.55 – 7.45 (m, 4H), 7.41 – 7.30 (m, 
8H), 7.27 – 6.92 (m, 65H), 5.83 – 5.78 (m, 1H), 5.61 (t, J = 2.4 Hz, 1H), 5.54 (t, J = 2.3 Hz, 
1H), 5.45 – 5.40 (m, 1H), 5.24 (s, 1H), 5.11 (s, 1H), 5.03 – 4.97 (m, 3H), 4.84 – 4.82 (m, 3H), 
4.79 – 4.67 (m, 7H), 4.62 – 4.26 (m, 14H), 4.17 – 4.08 (m, 2H), 4.02 – 3.90 (m, 6H), 3.87 – 
3.75 (m, 9H), 3.72 – 3.48 (m, 14H), 3.44 – 3.26 (m, 5H), 3.11 – 3.02 (m, 2H), 1.48 – 1.38 (m, 
4H), 1.26 (d, J = 9.1 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 165.98, 165.52, 165.43, 165.38, 
156.51, 138.66, 138.53, 138.49, 138.29, 138.21, 138.10, 138.05, 137.90, 137.81, 137.66, 
137.14, 136.79, 136.76, 133.52, 133.43, 133.27, 133.22, 130.26, 130.05, 129.99, 129.90, 
129.78, 129.34, 128.63, 128.55, 128.43, 128.35, 128.28, 128.17, 128.14, 128.02, 127.97, 
127.88, 127.81, 127.77, 127.71, 127.56, 127.47, 127.34, 100.24, 99.87, 99.28, 98.87, 97.64, 
97.55, 79.24, 79.11, 78.97, 78.61, 78.50, 75.33, 75.21, 75.12, 74.93, 74.58, 74.42, 74.10, 73.99, 
73.40, 72.78, 72.49, 71.91, 71.81, 71.75, 71.38, 71.24, 71.06, 70.49, 69.63, 69.57, 69.23, 68.81, 
67.84, 66.69, 66.02, 65.87, 62.59, 62.27, 61.94, 41.05, 29.87, 29.14, 23.54; m/z (HRMS+) 
2708.198 [M + H]+ (C161H168NO37 requires 2708.136). 




Deprotection of 5 as described in Module G and H, followed by purification using 
preparative HPLC (Method L) afforded compound 11  (3.1 mg, 2.88 µmol, 62% over two 
steps).1H NMR (600 MHz, D2O) δ 5.15 (s, 1H), 5.14 (s, 1H), 5.07 (s, 1H), 5.05 (s, 1H), 4.95 (s, 
1H), 4.87 (s, 1H), 4.12 – 3.54 (m, 38H), 3.02 (t, J = 7.7 Hz, 2H), 1.74 – 1.65 (m, 4H), 1.52 – 
1.41 (m, 2H); 13C NMR (150 MHz, D2O) δ 102.24 , 99.22, 99.11, 98.88, 78.72, 73.24, 73.17, 
72.73, 71.17, 71.08, 70.83, 70.57, 70.38, 69.93, 67.55, 66.64, 66.61, 66.58, 66.50, 66.42, 65.78, 
65.58, 65.11, 60.99, 60.96, 60.86, 39.29, 27.95, 26.49, 22.43; m/z (HRMS+) 1076.425 [M + 
H]+ (C41H73NO31 requires 1076.423).  






 Synthesis of α-(1,6) linear α-(1,2) branched dodecamannoside (6)  
 
Procedure A: 
 Module Conditions 
 A: Resin Preparation for Synthesis   
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 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -40 °C for 5 min, -20 °C for 30 min 
 
2  
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 




F: Lev Deprotection 
B: Acidic Wash with TMSOTf Solution 
3x C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
 
BB1 13 eq, -40 °C for 5 min, -20 °C for 30 min 
Procedure B: 
 Module Conditions 




 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 20 min 
 
2  
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
BB2 6.5 eq, -20 °C for 5 min, 0 °C for 20 min 
 
 
   
E: Lev Deprotection 
B: Acidic Wash with TMSOTf Solution 
3x C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 20 min 
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Cleavage from the solid support as described in Post-synthesizer manipulations followed 
by purification using a preparative HPLC (Method B), to provide the fully protected branched 
dodecasaccharide 6. For procedure A, 2.2 mg, 0.75 μmol, 6%, based on resin loading. For 
procedure B, 30 mg, 6.05 μmol, 48%, based on resin loading. 
Crude NP-HPLC of dodecasaccharide 6 A) Procedure A. B) Procedure B  (ELSD trace, 
Method A, tR = 31.3 min) 
 
1H NMR (600 MHz, CDCl3) δ 8.18 – 8.14 (m, 8H), 8.11 – 8.08 (m, 2H), 8.06 – 8.00 (m, 
6H), 7.96 (d, J = 7.7 Hz, 2H), 7.56(t, J = 7.5 Hz, 1H), 7.54 – 7.34 (m, 25H), 7.33 – 7.00 (m, 
116H), 5.88 (s, 1H), 5.82 – 5.78 (m, 4H), 5.72 (s, 1H), 5.67 (s, 1H), 5.64 – 5.60 (m, 2H), 5.30 
(s, 1H), 5.12 (s, 1H), 5.09 – 5.01 (m, 8H), 4.93 (s, 1H), 4.90 – 4.74 (m, 20H), 4.67 (dd, J = 10.9, 
6.7 Hz, 2H), 4.63 – 4.29 (m, 25H),  4.27 (s, 1H), 4.22 (dd, J = 9.0, 3.1 Hz, 1H), 4.12 –3.98 (m, 
11H), 3.95 – 3.30 (m, 45H), 3.16 (s, 2H), 1.50 – 1.45 (m, 4H), 1.35 – 1.32 (m, 2H);  13C NMR 
(152 MHz, CDCl3) δ 165.99, 165.76, 165.73, 165.67, 165.53, 165.44, 165.39, 165.31, 156.52, 
138.75, 138.61, 138.57, 138.49, 138.38, 138.31, 138.25, 138.08, 138.00, 137.91, 137.79, 
137.73, 137.69, 137.63, 137.57, 136.83, 133.44, 133.21, 130.14, 130.06, 130.00, 129.90, 
129.81, 128.78, 128.71, 128.62, 128.62, 128.47, 128.40, 128.31, 128.17, 128.11, 127.88, 
127.81, 127.77, 127.56, 127.50, 127.39, 127.26, 127.11, 100.32, 99.57, 99.33, 99.04, 98.70, 
98.65, 98.55, 98.43, 98.27, 98.01, 97.71, 78.73, 78.44, 78.37, 78.31, 78.24, 75.32, 75.19, 75.12, 
74.34, 74.05, 73.95, 73.90, 73.59, 71.97, 71.86, 71.78, 71.68, 71.55, 71.47, 71.44, 71.38, 71.24, 




65.95, 65.88, 41.10, 29.86, 29.19, 23.58. m/z (HRMS+) 2716.056 [2M + Na]++ 
(C323H323NO73Na  requires 2716.074). 
 
 
Deprotection of 6 as described in Modules G and H, followed by purification using 
preparative HPLC (Method L) afforded compound 12. (2.3 mg, 1.21 µmol, 20% over two 
steps).1H NMR (700 MHz, D2O) δ 5.17 (s, 1H), 5.15 (s, 1H), 5.08 – 5.06 (m, 2H), 4.96 (s, 1H), 
4.92 (d, J = 6.1 Hz, 5H), 4.89 (s, 1H), 4.13 – 4.10 (m, 2H), 4.06 (s, 2H), 4.02 (d, J = 4.6 Hz, 
8H), 4.00 – 3.95 (m, 8H), 3.94 – 3.91 (m, 3H), 3.91 – 3.82 (m, 19H), 3.81 – 3.74 (m, 20H), 3.73 
– 3.66 (m, 5H), 3.60 (d, J = 10.1, 6.1 Hz, 1H), 3.03 (t, J = 7.6 Hz, 2H), 1.75 – 1.67 (m, 4H), 
1.53 – 1.42 (m, 2H); 13C NMR (175 MHz, D2O) δ 102.29, 102.20, 99.87, 99.42, 99.40, 99.33, 
99.28, 98.16, 98.07, 80.47, 78.79, 78.71, 76.13, 73.46, 73.26, 73.21, 72.78, 72.37, 71.20, 71.11, 
70.99, 70.90, 70.88, 70.81, 70.77, 70.66, 70.61, 70.59, 70.42, 70.19, 70.04, 69.98, 69.96, 69.79, 
69.03, 67.61, 67.24, 66.81, 66.69, 66.63, 66.56, 66.54, 66.47, 65.63, 65.54, 65.47, 65.16, 61.18, 
61.05, 61.00, 60.91, 39.37, 28.03, 26.65, 24.46, 23.23, 22.53. m/z (HRMS+) 1886.677 [M + 
H]+ (C71H123NO56 requires 1886.688). 
RP-HPLC of purified dodecasaccharide 12 (ELSD trace, Method J, tR = 24.2 min) 
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 Synthesis of α-(1,6) linear α-(1,2) branched octaarabinomannoside (7) 
 
Procedure A 
 Module Conditions 
 A: Resin Preparation for Synthesis   
 
6 
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -40 °C for 5 min, -20 °C for 30 min 
 
2  
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
BB3 13 eq, -40 °C for 5 min, -20 °C for 30 min 
 
Procedure B 
 Module Conditions 
 A: Resin Preparation for Synthesis   
 
6 
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 20 min 
 
2  
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 






Cleavage from the solid support as described in Post-synthesizer manipulation followed by 
purification using a preparative HPLC (Method B), to provide the fully protected linear 
octasaccharide 7. For procedure A 4 mg, 1.10 μmol, 9%, based on resin loading. For procedure 
B 25 mg, 6.8 μmol, 56%, based on resin loading. 
 Crude NP-HPLC of octasaccharide 7 A) Procedure A. B) Procedure B (ELSD trace, 
Method A, tR = 28.6 min) 
 
1H NMR (400 MHz, CDCl3) δ 8.19 – 8.09 (m, 12H), 8.06 – 8.01 (m, 4H), 7.83 – 7.76 (m, 
4H), 7.62 – 7.56 (m, 1H), 7.53 – 7.06 (m, 90H), 6.98 – 6.89 (m, 4H), 5.88 – 5.74 (m, 6H), 5.62 
(dd, J = 3.3, 1.9 Hz, 1H), 5.56 (dd, J = 7.9, 2.8 Hz, 2H), 5.42 (s, 1H), 5.37 – 5.30 (m, 2H), 5.10 
– 5.01 (m, 6H), 4.90 – 4.76 (m, 12H), 4.66 (d, J = 11.4 Hz, 1H), 4.54 (d, J = 11.0 Hz, 1H), 4.48 
– 4.31 (m, 12H), 4.26 – 4.18 (m, 1H), 4.13 (d, J = 3.6 Hz, 1H), 4.09 – 3.99 (m, 8H), 3.99 – 3.90 
(m, 7H), 3.90 – 3.81 (m, 4H), 3.79 – 3.71 (m, 6H), 3.67 (d, J = 8.6 Hz, 3H), 3.58 (t, J = 10.4 
Hz, 3H), 3.51 – 3.35 (m, 5H), 3.19 – 3.11 (m, 2H), 1.52 – 1.42 (m, 4H), 1.36 – 1.32 (m, 2H); 
13C NMR (150 MHz, CDCl3) δ 165.95, 165.81, 165.57, 165.47, 165.29, 165.02, 138.54, 138.51, 
138.47, 138.45, 138.40, 138.22, 137.91, 137.60, 137.55, 137.49, 137.26, 133.49, 133.46, 
133.42, 133.25, 133.21, 133.16, 133.13, 133.06, 129.96, 129.91, 129.82, 129.73, 129.68, 
129.59, 129.14, 128.90, 128.59, 128.50, 128.44, 128.38, 128.29, 128.24, 128.17, 128.15, 
128.12, 127.99, 127.63, 127.59, 127.37, 127.30, 127.21, 127.07, 127.04, 126.97, 105.99, 
105.78, 98.45, 98.44, 98.09, 97.83, 83.50, 83.22, 81.55, 81.44, 78.55, 78.17, 77.97, 75.13, 
75.01, 74.97, 74.18, 73.99, 73.87, 73.79, 73.73, 73.68, 71.77, 71.60, 71.54, 71.38, 71.30, 71.25, 
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71.20, 71.15, 70.97, 70.87, 70.70, 70.04, 69.03, 68.53, 68.41, 68.36, 68.07, 67.76, 67.73, 66.51, 
66.08, 65.81, 65.79, 65.75, 65.64, 65.53, 62.19, 40.92, 29.74, 29.00, 23.39; m/z (HRMS+) 
3617.345 [M + Na]+ (C213H207NO51Na requires 3617.352). 
 
Deprotection of 7 as described  in Module G and I, followed by purification using 
preparative HPLC (Method L) afforded compound 13. (1.8 mg, 1.34 µmol, 26% over two 
steps).1H NMR (700 MHz, D2O) δ 5.13 (s, 1H), 5.11 (s, 1H), 4.94 – 4.91 (m, 5H), 4.89 (s, 1H), 
4.25 (s, 1H), 4.16 (d, J = 6.7 Hz, 2H), 4.13 (s, 1H), 4.04 (s, 1H), 4.01 (s, 5H), 3.97 (q, J = 11.5, 
9.6 Hz, 8H), 3.93 – 3.72 (m, 28H), 3.68 (dd, J = 11.8, 4.5 Hz, 1H), 3.62 – 3.57 (m, 1H), 3.02 (t, 
J = 7.7 Hz, 3H), 1.74 – 1.67 (m, 3H), 1.53 – 1.43 (m, 2H); 13C NMR (151 MHz, d2o) δ 107.32, 
107.18, 99.82, 99.35, 99.31, 99.26, 83.88, 82.03, 80.83, 80.76, 76.59, 76.44, 70.90, 70.85, 
70.76, 70.62, 70.49, 69.99, 69.91, 69.86, 67.56, 66.68, 66.57, 66.52, 65.44, 61.10, 39.30, 27.96, 
26.51, 22.47. m/z (HRMS+) 1340.501. [M + H]+ (C51H89NO39 requires 1340.508). 
 







 Synthesis of α-(1,6) α-(1,5) linear dodecaarabinomannoside (8) 
 
Procedure A: 
 Module Conditions 
 A: Resin Preparation for Synthesis   
 
6 
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -40 °C for 5 min, -20 °C for 30 min 
 
6  
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 




  Module Conditions 




B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 




B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
BB3 6.5 eq, -20 °C for 5 min, 0 °C for 20 min 
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Cleavage from the solid support as described in Post-synthesizer manipulations followed 
by purification using a preparative HPLC (Method B), to provide the fully protected linear 
dodecasaccharide 8. For procedure A: 4 mg, 0.80 μmol, 7%, based on resin loading. For 
Procedure B: 38 mg, 7.38 μmol, 61%, based on resin loading. 
 Crude NP-HPLC of dodecasaccharide 8  . A) Procedure A. B) Procedure B (ELSD trace, 




1H NMR (600 MHz, CDCl3) δ 8.17 – 7.99 (m, 24H), 7.90 – 7.75 (m, 12H), 7.61 – 7.05 (m, 
115H), 6.98 – 6.88 (m, 4H), 5.86 – 5.74 (m, 6H), 5.64 – 5.54 (m, 11H), 5.41 – 5.34 (m, 6H), 
5.31 (s, 1H), 5.15 – 4.99 (m, 7H), 4.89 – 4.74 (m, 11H), 4.67 (d, J = 11.4 Hz, 1H), 4.58 – 4.51 
(m, 3H), 4.48 – 4.21 (m, 10H), 4.15 – 3.37 (m, 50H), 3.20 – 3.11 (m, 2H); 13C NMR (100 MHz, 
CDCl3) δ 165.76, 165.66, 165.60, 165.22, 138.64, 138.59, 137.79, 137.68, 133.64, 133.54, 
133.44, 133.21, 130.15, 129.96, 129.89, 129.76, 129.26, 129.15, 128.78, 128.63, 128.47, 
128.35, 127.82, 127.77, 127.37, 127.24, 127.12, 106.01, 98.64,   98.28, 83.76, 83.48, 82.19, 
81.65, 81.59, 75.32, 75.20, 71.48, 71.08, 69.22, 68.61, 66.72, 66.25, 65.97, 29.86, 29.19; m/z 





Deprotection of 8 as described in Modules G and I, followed by purification using 
preparative HPLC (Method L) afforded compound 14 (3.6 mg, 1.90 µmol, 25% over two 
steps)1H NMR (700 MHz, D2O) δ 5.13 – 5.12 (m, 6H), 4.94 – 4.91 (m, 5H), 4.89 (s, 1H), 4.26 
– 4.22 (m, 5H), 4.17 – 4.15 (m, 6H), 4.13 – 4.12 (m, 1H), 4.06 – 3.94 (m, 17H), 3.94 – 3.72 (m, 
37H), 3.67 (dd, J = 11.6, 4.3 Hz, 1H), 3.61 – 3.58 (m, 1H), 3.02 (t, J = 7.7 Hz, 2H), 1.74 – 1.66 
(m, 4H), 1.53 – 1.43 (m, 2H); 13C NMR (176 MHz, D2O) δ 107.48, 107.37, 107.25, 99.87, 
99.39, 99.35, 99.30, 99.27, 83.92, 82.31, 82.30, 82.06, 80.87, 80.80, 80.78, 76.68, 76.63, 76.47, 
70.94, 70.90, 70.88, 70.81, 70.78, 70.76, 70.69, 70.65, 70.53, 70.03, 69.96, 69.90, 67.59, 66.83, 
66.72, 66.60, 66.56, 66.54, 66.52, 66.29, 65.63, 65.52, 65.47, 61.13, 46.68, 39.33, 28.01, 26.54, 
22.51. m/z (HRMS+) 1868.680 [M + H]+ (C71H121NO55  requires 1868.677). 
RP-HPLC of purified dodecasaccharide 14 (ELSD trace, Method J, tR = 29.6 min) 
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 Module Conditions 
 A: Resin Preparation for Synthesis   
  B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -40 °C for 5 min, -20 °C for 30 min 
 
2  
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
BB2 6.5 eq, -40 °C for 5 min, -20 °C for 30 min 
  
 
B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -40 °C for 5 min, -20 °C for 30 min 
 
6 
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
BB3 13 eq, -40 °C for 5 min, -20 °C for 30 min 
 
 
   
F: Lev Deprotection 
B: Acidic Wash with TMSOTf Solution 
2x C: Thioglycoside Glycosylation 
E: Fmoc Deprotection 
 
 







 Module Conditions 
 A: Resin Preparation for Synthesis   
  B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 20 min 
 
2  
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
BB2 6.5 eq, -20 °C for 5 min, 0 °C for 20 min 
  B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 20 min 
 
6 
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 




F: Lev Deprotection 
B: Acidic Wash with TMSOTf Solution 
2x C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 20 min 
 
Cleavage from the solid support as described in Post-synthesizer manipulations followed 
by purification using a preparative HPLC (Method B, tR = 38.8 min), to provide the fully 
protected branched dodecasaccharide 9. For procedure A: 2 mg, 0.411 μmol, 3%, based on resin 
loading.  For procedure B: 16 mg, 3.22 μmol, 26%, based on resin loading. 
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Crude NP-HPLC of dodecasaccharide 9 . A) Procedure A. B) Procedure B  (ELSD trace, 
Method A, tR = 38.8 min) 
 
1H NMR (600 MHz, Chloroform-d) δ 8.15 – 8.07 (m, 3H), 8.05 – 7.98 (m, 25H), 7.96 – 
7.92 (m, 2H), 7.87 (dd, J = 8.2, 1.4 Hz, 4H), 7.83 (ddd, J = 8.3, 6.8, 1.4 Hz, 12H), 7.76 (dt, J = 
8.4, 1.7 Hz, 7H), 5.88 (d, J = 2.4 Hz, 1H), 5.75 (s, 1H), 5.69 – 5.64 (m, 1H), 5.64 – 5.54 (m, 
19H), 5.16 (d, J = 1.7 Hz, 1H), 5.06 (d, J = 5.7 Hz, 6H), 4.97 (d, J = 1.9 Hz, 1H), 4.92 – 4.33 
(m, 57H), 4.27 – 3.59 (m, 61H), 3.57 – 3.31 (m, 8H), 3.13 (q, J = 6.8 Hz, 4H), 1.56 – 1.50 (m, 
4H), 1.46 (t, J = 7.5 Hz, 2H), 1.34 – 1.28 (m, 2H).13C NMR (151 MHz, cdcl3) δ 166.02, 165.58, 
165.55, 165.52, 165.42, 165.33, 165.06, 165.02, 138.62, 138.37, 138.07, 137.99, 137.91, 
137.79, 136.64, 133.45, 133.35, 133.29, 133.24, 133.09, 133.06, 133.01, 129.87, 129.82, 
129.78, 129.70, 129.67, 129.61, 129.58, 129.18, 129.10, 129.00, 128.92, 128.63, 128.54, 
128.47, 128.45, 128.43, 128.36, 128.36, 128.25, 128.24, 128.22, 128.19, 128.17, 128.14, 
128.11, 128.07, 128.04, 127.99, 127.99 127.94, 127.83, 127.74, 127.71, 127.69, 127.59, 
127.49, 127.41, 127.32, 127.26, 127.14, 126.90, 106.00, 105.83, 105.80, 99.34, 97.52, 83.58, 
83.29, 82.02, 81.91, 81.63, 81.53, 81.46, 78.37, 77.96, 77.65, 75.13, 74.92, 74.83, 74.05, 73.26, 
71.79, 71.66, 71.59, 71.26, 71.16, 70.65, 66.51, 66.08, 65.79, 65.72, 65.61, 62.45, 62.28, 40.91, 







Deprotection of 9 as described in Modules G and I, followed by purification using 
preparative HPLC (Method L) afforded compound 15 (1.0 mg, 0.53 µmol, 17% over two 
steps)1H NMR (700 MHz, D2O) δ 5.17 (s, 1H), 5.15 (s, 1H), 5.12 (s, 6H), 5.07 (s, 1H), 5.06 (s, 
1H), 4.95 (s, 1H), 4.88 (s, 1H), 4.27 (s, 5H), 4.17 (d, J = 10.3 Hz, 6H), 4.11 (s, 3H), 4.07 – 3.94 
(m, 15H), 3.94 – 3.90 (m, 7H), 3.86 – 3.81 (m, 15H), 3.80 – 3.66 (m, 16H), 3.61 – 3.57 (m, 
1H), 3.03 (t, J = 7.6 Hz, 2H), 1.74 – 1.68 (m, 4H), 1.52 – 1.44 (m, 2H); 13C NMR (176 MHz, 
D2O) δ 107.5, 107.4, 102.3, 99.9, 99.6, 98.2, 84.0, 82.3, 82.1, 80.9, 80.8, 80.8, 78.8, 76.7, 76.7, 
76.7, 76.5, 73.3, 73.2, 71.2, 70.9, 70.9, 70.8, 70.5, 70.5, 70.1, 70.0, 70.0, 67.6, 66.9, 66.9, 66.8, 
66.7, 66.7, 66.7, 66.5, 66.5, 66.3, 65.9 61.2, 61.1, 61.0, 43.8, 39.4, 28.0, 26.6, 22.5. m/z 
(HRMS+) 1868.669 [M + H]+ (C71H121NO55  requires 1868.677). 
 
RP-HPLC of purified dodecasaccharide 15 (ELSD trace, Method K, tR = 28.5 min) 
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 Module Conditions 




B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation 
D: Capping 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 30 min 
E: Fmoc Deprotection  
 
After checking the outcome of the reaction with MALDI (Module G1), methanolysis on 
resin was performed (Module H1). Cleavage from the solid support (Module G) and 
hydrogenolysis (Module I) followed by purification using preparative HPLC (Method K) 
afforded compound 16 (4.8 mg, 42% based on resin loading). 
Analytical data for 16: 1H NMR (400 MHz, D2O) δ 4.73 (s, 1H), 4.71 (s, 1H), 4.67 (s, 1H), 
3.80 (m, 2H), 3.78 – 3.71 (m, 10H), 3.71 – 3.49 (m, 15H), 2.82 (t, J = 7.7 Hz, 2H), 1.56 – 1.43 
(m, 4H), 1.27 (h, J = 6.5, 6.0 Hz, 2H). 13C NMR (101 MHz, D2O) δ 99.76, 99.28, 99.13, 72.58, 
70.77, 70.63, 70.53, 70.39, 69.83, 67.49, 66.60, 66.43, 65.38, 60.79, 39.23, 27.91, 26.46, 22.42. 








RP-HPLC of 16 (ELSD trace, Method J, tR = 23.2 min) 
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 Module Conditions 
 A: Resin Preparation for Synthesis   
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 20min 
 
 
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection  
F: Lev Deprotection 
 
BB2 6.5 eq, -20 °C for 5 min, 0 °C for 20min 
 
  2 
B: Acidic Wash with TMSOTf Solution 
C: 2* Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 20min 
 
After checking the outcome of the reaction with MALDI (Module G1), methanolysis on 
resin was performed (Module H1). Cleavage from the solid support (Module G) and 
hydrogenolysis (Module I) followed by purification using preparative HPLC (Method K) 







RP-HPLC of 17 (ELSD trace, Method J, tR = 21.2 min) 
 
Analytical data for 17: 1H NMR (700 MHz, D2O) δ 5.14 (s, 1H), 5.04 (s, 1H), 4.98 (s, 1H), 
4.95 (s, 2H), 4.90 (s, 1H), 4.11 (s, 1H), 4.06 – 4.02 (m, 1H), 4.04 – 3.99 (m, 5H), 3.99 – 3.91 
(m, 6H), 3.90 – 3.82 (m, 8H), 3.79 (dt, J = 21.7, 8.6 Hz, 10H), 3.74 (d, J = 9.9 Hz, 1H), 3.72 – 
3.66 (m, 3H), 3.60 (d, J = 9.3 Hz, 1H), 3.04 (t, J = 7.7 Hz, 2H), 1.73 (m, 4H), 1.49 (tq, J = 14.8, 
7.1 Hz, 2H). 13C NMR (176 MHz, D2O) δ 102.30, 99.93, 99.45, 99.45, 99.19, 97.86, 72.74, 
71.33, 71.19, 71.11, 70.94, 70.94, 70.76, 70.61, 70.53, 70.45, 70.04, 70.02, 67.65, 66.82, 66.77, 
66.65, 66.56, 66.52, 65.68, 60.97, 39.42, 28.04, 26.61, 22.53. m/z (HRMS+) 1076.428 [M + 
H]+ (C41H74NO31 requires 1076.424). 
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 Synthesis of 100-mer polymannoside (18) 
 
 
Cycles Module Conditions 
 A: Resin Preparation for Synthesis  
 
       40 
B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation   
D: Capping  
E: Fmoc Deprotection 
 
BB1 (5 equiv)-20 °C for 5 min, 0 °C for 20 min 
 
       40 
B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation  
D: Capping  
E: Fmoc Deprotection 
 
BB1 (6 equiv)-20 °C for 5 min, 0 °C for 40 min 
 
       20 
B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation  
D: Capping  
E: Fmoc Deprotection 
 
BB1 (6.5 equiv)-20 °C for 5 min, 0 °C for 60 min 
 
The product was cleaved from the solid support as described in the post-synthesizer 
manipulations followed by purification using normal phase preparative HPLC with a YMC diol 
column.(Method K) Linear gradient: Hex – 50% EtOAc as eluents [isocratic 50% EtOAc (5 
min), linear gradient to 50% EtOAc (5 min), linear gradient to 75% EtOAc (30 min), linear 









HPLC of crude 100-mer 18 (UV 280 nm trace, Method J, tR = 17.6min) 
 
 
HPLC of purified 100-mer 18 (UV 280 nm trace, Method J, tR = 17.6 min) 
 
Analytical data for 100-mer polymannose 18: Yield 5% over 201 steps. 1H NMR (700 
MHz, Chloroform-d) δ 8.16 (d, J = 7.3 Hz, 200H), 7.48 (dt, J = 13.6, 7.2 Hz, 250H), 7.21 – 
6.99 (m, 1060H), 5.83 (s, 100H), 5.03 (s, 100H), 4.86 (d, J = 11.5 Hz, 100H), 4.78 (d, J = 10.8 
Hz, 100H), 4.40 (d, J = 10.8 Hz, 100H), 4.31 (d, J = 11.7 Hz, 100H), 4.04 – 3.98 (m, 100H), 
3.96 (t, J = 9.5 Hz, 100H), 3.70 (d, J = 10.6 Hz, 100H), 3.56 (d, J = 9.5 Hz, 1H), 3.40 (d, J = 
11.0 Hz, 100H), 3.16 – 3.15 (m, 2H), 1.58 – 1.53 (m, 2H), 1.49 (m, 2H), 1.36 – 1.32 (m, 2H); 
13C NMR (176 MHz, Chloroform-d) δ 165.54, 138.49, 137.52, 133.32, 130.02, 129.87, 128.66, 
128.37, 128.34, 128.14, 127.69, 127.30, 127.01, 98.56, 78.21, 75.00, 73.72, 71.30, 70.90, 68.39, 
65.73, 29.12; m/z (MALTI-TOF) 44888.4201 [M + Na]+ (C2713H2619NO603Na requires 
44877.4201). 
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MALDI-TOF of protected 100-mer (18) 
 
HPLC of purified 100-mer-with 3 benzyl groups cleaved 19 (UV 280 nm trace, Method J, 
tR = 17.6 min) 
 
 
Analytical data for 100-mer polymannose 19: Yield 3% over 201 steps. 1H NMR (600 
MHz, Chloroform-d) δ 8.18 – 8.13 (m, 200H), 7.52 – 7.44 (m, 250H), 7.19 – 7.05 (m, 1045H), 
5.82 (s, 100H), 5.03 (d, J = 1.7 Hz, 100H), 4.86 (d, J = 11.6 Hz, 100H), 4.77 (d, J = 10.8 Hz, 
100H), 4.40 (d, J = 10.8 Hz, 100H), 4.31 (d, J = 11.7 Hz, 100H), 4.03 – 3.93 (m, 200H), 3.70 
(d, J = 10.8 Hz, 100H), 3.56 (d, J = 9.6 Hz, 100H), 3.40 (q, J = 9.5 Hz, 100H); 13C NMR (151 
MHz, Chloroform-d) δ 165.68, 138.62, 137.64, 133.46, 130.14, 130.00, 128.79, 128.51, 128.48, 
128.28, 127.83, 127.43, 127.14, 98.69, 78.34, 75.13, 73.84, 71.43, 71.02, 68.52, 65.85; m/z 




MALDI-TOF of protected 100-mer with 3 benzyl groups cleaved (19) 
 
 
Deprotection of 100-mer polymannoside:  
 
Methanolysis (Module G). To a solution of protected oligosaccharide 18 in 
methanol:CH2Cl2 (1:1), was added sodium methoxide in methanol (0.5 M, pH 13) and stirred 
at room temperature for 16 h, neutralized with Amberlite ion exchange (H+) resin, filtered and 
concentrated in vacuo and carried forward directly into hydrogenolysis without purification.  
Hydrogenolysis (Module H). The product of Zemplén methanolysis was dissolved in 
EtOAc:t-BuOH:H2O (2:1:1) and transferred to cylindrical vials. Pd-C (10%) (100 weight %) 
was added and the reaction mixture was stirred under autoclave with hydrogen 5 psi pressure 
for 72 h. The reaction mixture were filtered through Celite and washed with methanol and water. 
The filtrates were concentrated in vacuo and purified on Synergy column (Method D) and 
lyophilized to give a pure compound 20. 
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Analytical data for 20:  1H NMR (700 MHz, D2O) δ 4.85 (s, 100H), 3.94 (s, 100H), 3.89 
(dd, J = 11.4, 5.5 Hz, 100H), 3.84 – 3.76 (m, 200H), 3.73 (d, J = 11.1 Hz, 100H), 3.67 (t, J = 
9.8 Hz, 100H), 3.61 (d, J = 10.1 Hz, 2H), 2.95 (d, J = 9.6 Hz, 2H), 2.80 (d, J = 1.7 Hz, 2H), 
1.70 – 1.55 (m, 4H); 13C NMR (176 MHz, Deuterium Oxide) δ 171.06, 99.39, 70.88, 70.74, 
70.03, 66.65, 65.57 ; m/z (MALTI-TOF) 16433.884 [M+Na]+ (C605H1013NO501Na requires 
16331.37). 







 Synthesis of 151-mer polymannoside by block coupling   
 
 30-mer Donor Synthesis (22) 
 
 
   Module Conditions 
 A: Resin Preparation for Synthesis  
 
  30 
B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation                                    
D: Capping  
E: Fmoc Deprotection 
 
BB1 (5 equiv)-20 °C for 5 min, 0 °C for 20 min 
  2x D: Capping   
 
The product was cleaved from the solid support as described in the post-synthesizer 
manipulations followed by purification using normal phase preparative HPLC with a YMC diol 
column. (Method F) Linear gradient: Hex – 35% EtOAc as eluents [isocratic 35% EtOAc (5 
min), linear gradient to 35% EtOAc (5 min), linear gradient to 60% EtOAc (30 min), linear 
gradient to 100% EtOAc (5 min)] 30-mer 22 eluted at 27.43 minutes. 
HPLC of 30-mer 22 (UV 280 nm trace, Method E, tR = 27.4min) 
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MALDI-TOF spectrum of 30-mer, 1-OH (22) 
   
Analytical data for 22:  1H NMR (400 MHz, Chloroform-d) δ 8.23 – 8.15 (m, 60H), 7.52 
(d, J = 7.0 Hz, 120H), 7.24 – 7.03 (m, 360H), 5.87 (t, J = 2.3 Hz, 30H), 5.06 (s, 30H), 4.89 (d, 
J = 11.4 Hz, 30H), 4.81 (d, J = 10.7 Hz, 30H), 4.43 (d, J = 10.7 Hz, 30H), 4.32 (d, J = 11.7 Hz, 
30H), 4.08 – 3.93 (m, 90H), 3.71 (d, J = 10.2 Hz, 30H), 3.57 (d, J = 9.3 Hz, 30H), 3.40 (d, J = 
11.2 Hz, 30H), 2.20 (s, OAc, 3H); 13C NMR (101 MHz, Chloroform-d) δ 165.54, 138.48, 
137.45, 133.39, 129.96, 129.89, 128.68, 128.44, 128.38, 128.15, 127.74, 127.30, 126.95, 98.52, 
78.21, 77.26, 74.99, 73.64, 71.29, 70.81, 68.30, 65.65, 20.78; m/z (MALTI-TOF) 13465.174 





 Synthesis of 30-mer glycosyl fluoride donor (23) 
 
To a solution of compound 22 (94 mg, 72.8 mol) in CH2Cl2 (2 mL) was added a solution 
of Deoxo-Fluor (110 L, 150 mol) at -30 C. The reaction was stirred for 30 minutes. The 
reaction was quenched with 2 mL of NaHCO3. The organic phase was extracted with aqueous 
citric acid, dried over MgSO4, filtered, concentrated and purified by preparative HPLC (Method 
F)to provide compound 23 (85 mg, 90% yield). 
HPLC of 30-mer 23 (ELSD trace, Method E, tR = 22.1 min) 
 
Analytical data for 23:  1H NMR (700 MHz, Chloroform-d) δ 8.21 – 8.17 (m, 60H), 7.51 
(qd, J = 8.0, 4.2 Hz, 90H), 7.21 – 7.08 (m, 300H), 5.85 (t, J = 2.4 Hz, 30H), 5.06 (d, J = 1.9 Hz, 
30H), 4.89 (d, J = 11.5 Hz, 30H), 4.80 (d, J = 11.0 Hz, 30H), 4.43 (d, J = 11.0 Hz, 30H), 4.35 
(dd, J = 11.6, 3.4 Hz, 30H), 4.03 (dd, J = 9.2, 3.2 Hz, 30H), 4.01 – 3.96 (m, 30H), 3.74 (d, J = 
11.1 Hz, 30H), 3.61 – 3.57 (m, 30H), 3.45 (dd, J = 10.4, 7.7 Hz, 30H), 2.20 (s, OAc, 3H); 13C 
NMR (101 MHz, Chloroform-d) δ 165.54, 138.47, 137.44, 133.39, 129.94, 129.89, 128.68, 
128.44, 128.38, 128.14, 127.74, 127.29, 126.94, 98.51, 78.21, 77.26, 76.09, 74.99, 73.63, 71.29, 
70.80, 68.29, 65.64, 31.02, 18.59; m/z (MALTI-TOF) 13448.270 [M + H]+ (C812H783FO181 
requires 13447.2049).  
2 Pushing the limits of AGA 
70 
 
 Automated synthesis of branched acceptor (24)  
 
 




A: Resin Preparation for Synthesis 
 
 
  4 
B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation   
D: Capping  
E: Fmoc Deprotection 
 
BB1 (6.5 equiv)-20 °C for 5 min, 0 °C for 20 min     
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation  
D: Capping  
F: Lev Deprotection 
E: Fmoc Deprotection 
 





B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation  
D: Capping 
E: Fmoc Deprotection 
 




  3 
B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation  
D: Capping 
E: Fmoc Deprotection 
 
BB1 (6.5 equiv) -20 °C for 5 min, 0 °C for 20 min 
 
 
 B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation  
D: Capping  
F: Lev Deprotection 
E: Fmoc Deprotection 
 





B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation  
D: Capping 
E: Fmoc Deprotection 
 




  3 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation  
D: Capping 
E: Fmoc Deprotection 
 






The product was cleaved from the solid support as described in the post-synthesizer 
manipulations followed by purification by using normal phase preparative HPLC with YMC 
diol column. (Method F) Linear gradient: Hex – 35% EtOAc as eluents [isocratic 35% EtOAc 
(5 min), linear gradient to 35% EtOAc (5 min), linear gradient to 60% EtOAc (30 min), linear 
gradient to 100% EtOAc (5 min)] 31-mer 24 eluted at 32.25 minutes. 
HPLC of crude 31-mer 24 (280nm trace, Method E, tR = 31.6 min) 
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MALDI-TOF of 31-mer acceptor (24) 
 
 Synthesis of branched 151-mer polymannoside 25 via block coupling 
 
 
To a solution of glycosyl donor 23 (41 mg, 6 eq) and glycosyl acceptor 24 (7 mg, 1 eq) in 
1mL of anhydrous CH2Cl2 was added activated 4Å molecular sieves (20 mg) at room 
temperature for 5 min protected from light. The reaction was cooled to -40 C and silver 
perchlorate (2.8 mg, 5 eq) and bis(cyclopentadienyl) hafnium dichloride (2.5 mg, 3 eq) were 
added.[5] This mixture was allowed to stir at same temperature for 30 minutes, resulted 
completion of the reaction. This mixture was quenched with Et3N diluted with CH2Cl2 and 




mL) The organic layer was dried over MgSO4 filtered, concentrated and purified by Preparative 
HPLC (Method H) with a YMC diol column. The pure compound 25 was isolated with (27 mg, 
78%). 
HPLC of crude 151-mer 25 (ELSD trace, Method G, tR = 30.7 min) 
 
 





Analytical data for 25:  1H NMR (700 MHz, Chloroform-d) δ 8.18 (d, J = 7.6 Hz, 302H), 
7.50 (dt, J = 13.3, 7.2 Hz, 453H), 7.23 – 7.04 (m, 1510H), 5.85 (d, J = 3.2 Hz, 151H), 5.05 (s, 
151H), 4.88 (d, J = 11.6 Hz, 151H), 4.80 (d, J = 10.9 Hz, 151H), 4.43 (d, J = 11.0 Hz, 151H), 
4.38 – 4.31 (m, 151H), 4.03 (dd, J = 9.3, 3.2 Hz, 151H), 3.98 (t, J = 9.5 Hz, 151H), 3.79 – 3.65 
(m, 151H), 3.58 (d, J = 9.6 Hz, 151H), 3.46 – 3.37 (m, 151H), 2.38 (s, OAc, 12H); 13C NMR 
(176 MHz, Chloroform-d) δ 165.54, 138.49, 137.51, 133.32, 130.01, 129.87, 128.65, 128.36, 
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128.34, 128.14, 127.69, 127.30, 127.02, 98.56, 78.20, 75.00, 73.72, 71.30, 70.90, 68.39, 65.72, 
31.94, 29, 22.70; m/z (MALTI-TOF) 67133.363 [M + Na]+ (C4049H3921NO908K requires 
67116.0675). 
 
MALDI-TOF of pure 151-mer (25) 
 
Deprotection of 151-mer polymannoside: 
 
 
Zemplén Methanolysis. Sodium methoxide in methanol (0.5 M, pH 13) was added to a 
solution of protected oligosaccharide (12 mg) 26 in methanol:CH2Cl2 (1:1), and stirred at room 
temperature for 16 h, neutralized with Amberlite ion exchange (H+) resin, filtered and 




Hydrogenolysis. The Zemplén methanolysis product was dissolved in EtOAc:t-
BuOH:H2O (2:1:1) and transferred to cylindrical vials. Pd-C (10%) (100 weight %) was added 
and the reaction mixture was stirred in hydrogen reactor with 5 psi pressure for 72 h. The 
reaction mixture were filtered through Celite and washed with methanol and water. The filtrates 
were concentrated in vacuo and purified on Size exclusion chromatography (Method I) TSKgel 
G3000 PWXL column and lyophilized to give a pure compound 27 in 1.8 mg (41% yield over 
two steps). 
HPLC of 151-mer 26 (ELSD trace, Method I, tR = 15.7 min) 
 
 
Analytical data for 26: 1H NMR (700 MHz, D2O) δ 4.92 (s, 151H), 4.01 (s, 151H), 3.98 – 
3.93 (m, 151H), 3.85 (d, J = 11.9 Hz, 302H), 3.80 (d, J = 11.2 Hz, 151H), 3.74 (t, J = 9.9 Hz, 
151H), 3.06-3.04 (m, 2H), 3.02 (s, 2H), 2.0 (d, J = 6.9 Hz, 2H), 1.33 (d, J = 6.9 Hz, 2H); 13C 
NMR (176 MHz, D2O) δ 99.35, 70.84, 70.70, 69.99, 66.61, 65.52; m/z (MALTI-TOF) 
24574.800 [M+H]+ (C911H1524NO756 requires 24574.076). 
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MALDI-TOF of 151-mer (26) 
  
 Glycan Imaging - ES-IBD.  
For the ES-IBD experiment, the solution of the synthesized glycans (linear pentamannoside 
16 and haxamannosides 11 and 17 were prepared by dissolving the powder in a water-ethanol 
1:1 mixture with approx. 0.1% ammonia hydroxide to result in a concentration of ~10-4 mol/L.  
Subsequently, negative charged gas phase ions of the glycans were generated by our home-built 
ES-IBD apparatus ( -1 for glycans 11, 16, 17), 2-3 kV on the emitter, 20 μl/h flow rate, current 
up to ~200 pA, about 10 min of deposition time). Before the deposition in UHV, the 
composition of the ion beam is monitored by a time-of-flight (ToF) mass spectrometer and 
purified by RF quadrupoles. The deposition took place in the ultrahigh vacuum (UHV) chamber 
with a base pressure of 2 × 10-10 mbar. The landing energy of the molecular ion beam was 
below 5 eV to avoid fragmentation.  
Before the deposition, the Cu (100) single crystal (Surface Preparation Laboratory, SPL) 
was cleaned via several cycles of Ar ion sputtering (1.2 kV, 20 min) and annealing (800 K, 
10min). After the cleaning, the substrate was cooled down to ~120 K and transferred with a low 
temperature (LT) UHV suitcase (~120 K, 2 × 10-10 mbar) to the deposition chamber. During 






STM measurements.  
After the deposition, the sample was kept at ~120 K and transferred with the LT-UHV 
suitcase to the LT-STM for imaging. In all the chamber involved in the sample transfer, the 
base pressure is below 8 × 10-10 mbar. The STM experiments are performed in a home-built 
LT-STM operated at 4.5 K and controlled by a Nanonis RC5 electronics. All STM 
measurements were performed with a chemical etched W tip.  
STM data analysis was performed using WSxM and OriginPro 2016. The interunit distance 
given in the paper is an average value taking into account only molecules where all features 
could be resolved in the STM measurement. For hexamannoside 11, four molecules were taken 
into account with four (1-6) interunit distances each averaging to 0.49 ± 0.06 nm and two (1-2) 
interunit distance averaging to 0.62 ± 0.04 nm. For hexamannose 17, three molecules were 
taken into account with four (1-6) interunit distances each averaging to 0.5 ± 0.04 nm and one 
(1-2) interunit distance averaging to 0.62 ± 0.02 nm. 
 
STM topography image of linear glycans. a,b  STM images of pentamannoside 16 showing 
different conformations on the surface. Scale bars are 1 nm. 




STM topography image of branched hexamannosides. a,b STM images of hexamannoside 
11 showing different conformations on the surface. The branching is clearly visible. The 
assignment of the linkage is possible due to measurements of the interunit distance and is 
assigned in the inset ((1,2) linkage in pink). c, d STM images of hexamannoside 17 showing 
different conformations on the surface. The branching is clearly visible. The assignment of the 
linkage is possible due to measurements of the interunit distance and is assigned in the inset 














3. Defined glycan structures as substrates to study marine 
hydrolases 
 
This chapter has been modified in part from the following article: 
Le Mai Hoang K., Pardo-Vargas A., Zhu Y., Yu Y., Loira M., Delbianco M., Seeberger 
P.H. Traceless Photolabile Linker Expedites the Chemical Synthesis of Complex 
Oligosaccharides by Automated Glycan Assembly J. Am. Chem. Soc. 2019, 141, 22, 9079-
9086. DOI: 10.1021/jacs.9b03769 
 
 Abstract 
Carbohydrate-degrading enzymes obtained from marine sources have been recognized as 
promising biocatalysts with high potential in biorefinery. Marine glycans with specific 
substitution patterns and length are required as substrates for the complete characterization of 
these enzymes. Automated Glycan Assembly (AGA) was employed to synthesize a collection 
of six linear α-(1,6)-mannosides and seven β-(1,3)-glucans with specific β-(1,6) and β-(1,4) 
substitution patterns. All of the compounds were obtained with a free reducing end using a 
traceless photolabile linker. The characterization of the putative mannanase GH76A from 
Salegentibacter sp. using synthetic glycans is also described. A detailed 3-D structure of the 
active site of GH76A was obtained after the co-crystallization of synthetic mannose tetramer 
with mutant mannanase GH76. Incubation of these synthetic α-(1,6)-mannosides with GH76A 
generated hydrolyzed glycans, this suggested that the enzyme GH76A function as an endo α-
(1,6)- mannanase.  
 Algae bloom as source of Carbohydrate-Active Enymes (CAZymes) 
Marine algae are major carbon sinks that convert carbon dioxide to carbohydrate materials 
such as laminarin.124 These carbohydrates are nutrient sources for bacterial colonies in marine 
surface waters.125 To digest these polysaccharides, bacteria use a vast number of carbohydrate-
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degrading enzymes. For example, the marine flavobacterium Formosa agariphila degrades the 
main cell wall polysaccharide of marine algae Ulva to single monosaccharides using 12 
different enzymes.126 Thus, the expression and characterization of hydrolitic enzymes can turn 
an unexplored polysaccharides source into a valuable and ecologically renewable 
bioresource.127 
Metagenomics studies of bacteria associated with the algal spring blooms, particularly 
Bacteriodetes, showed a high abundance of hydrolytic Carbohydrate-Active Enzymes 
(CAZymes).128,129 There are over 400 putative genetic clusters (PULs), which encodes for 
hydrolytic CAZymes in the North Sea, and most of these clusters have not yet been studied.130 
Cloning and recombinant expression of CAZyme sequences permitted the elucidation of the 
degradation pathways for several polysaccharides such as rhamnogalacturonan,131  xyloglucan 
and alpha-mannan.132 
The enzymes belonging to the class of α-mannanase are of great interest because of their 
diverse functions such as glycoprotein maturation,133 complex dietary polysaccharides 
processing by human gut microbiota132 and fungal cell wall assembly.134,135 One interesting 
putative genetic cluster is α-mannan PUL because most of the encoded enzymes are distantly 
related or their function is still completely unknown. Putative mannanase GH76A from 
Salegentibacter sp. may degrade α-mannans. Here the characterization of the putative 
mannanase GH76A using synthetic glycans is described. Automated Glycan Assembly (AGA) 
was employed to synthesize a collection of six linear α-(1,6)-mannosides with a free reducing 
end using a traceless photolabile linker.114 
 AGA of linear mannosides 
The characterization of the putative mannanase GH76A required the synthesis of a collection 
of natural α-(1,6)-oligomannosides with a free reducing end. Therefore, BB 1, bearing an Fmoc 
protecting group at C-6 for chain elongation, was coupled to a Merrifield resin equipped with 
a recently newly developed traceless photo-cleavable linker 28. The oligosaccharide chain was 
assembled by using iterative optimized AGA cycles, which consisted of four modules (Figure 
3.1). An acidic wash module B prepared the resin for the glycosylation by quenching any 
remaining base from the previous step. In the glycosylation module C, thioglycoside donor 1 
was coupled to the resin upon activation with NIS and TfOH (from -20 °C to 0 °C) Next, a 





incomplete glycosylation and finally module E removes the temporary Fmoc group (14 min) 
revealing a free hydroxyl group for  subsequentent glycosylation.108 After photocleaveage of 
the polysaccharide from the resin, a fully protected α-(1,6)-oligomannoside was obtained with 
a benzyl alchohol in the anomeric position that was later removed by hydrogenolysis during 
global deprotection. 
Cycles Module Conditions 
 A: Resin Preparation for Synthesis  
 
n 
B: Acidic Wash with TMSOTf Solution 
C: Thioglycoside Glycosylation 
D: Capping 
E: Fmoc Deprotection 
 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 30 min 
 
Figure 3.1 A) AGA scheme of α-(1,6)-mannosides 29-34 ranging from dimer (n=2) to heptamer 
(n=7) using a traceless photocleavable linker 28 and BB 1. B) AGA sequence for α-(1,6)-
mannosides 29-34. Modules B-E were repeated n times until the desired sequence was obtained. 
Linear α-(1,6)-dimannoside 29 was synthesized using two coupling cycles (n=2) and 6.5 
equivalents of mannose BB 1. During each cycle, no side products of incomplete glycosylation 
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were observed, and the crude product was purified using normal phase HPLC to obtain 
dimannoside 29 in 50% yield, based on resin loading. Following the same AGA procedure for 
compounds 30-34 no deletion sequence was observed even for the heptamer 34. For the 
deprotection of 29, the protected oligosaccharide was dissolved in a mixture MeOH and DCM, 
followed by the addition of 0.1 ml 1M solution of NaOMe in MeOH. After 12 h, the solution 
was neutralized with Amberlite IR-120. The crude compound was directly used for 
hydrogenolysis with Pd/C inside an H2 bomb with 60 psi pressure for 16 hours. The reaction 








Table 3.1 Yields for linear oligomannosides 29 to 34 based on resin loading after AGA 
and two steps global deprotection.  
All deprotected compounds 35 – 40 were purified using RP-HPLC. First attempts, using a 
C-18 synergy column, were not successful since mannoside 35 eluted with the injection peak. 
Purification using a Hypercarb column gave 35 in 20% yield after AGA and two steps 
deprotection. For deprotection of mannosides 30-34 the same protocol was followed to obtain 
the fully deprotected α-(1,6) mannosides 36-40 (Table 3.1) as a mixture of α and β isomers at 
the free reducing end. 
 






With these optimized conditions, a total of six mannosides containing α-(1,6)-Man, 
linkages were synthesized by automated glycan assembly in high yields, using monosaccharide 
building block 1 and the new traceless linker 28 (Figure 3.2). 
 Functional characterization of mannosylhydrolase GH76A 
 GH76A crystal structures with synthetic mannosides 
Dr Solanki (from the Max Planck Institute for Marine Microbiology) cloned, expressed 
and purified GH76AWild Type (GH76AWT) using heterologous expression system for 
structural and functional characterization. To study interfacial binding in the absence of 
catalysis, a structurally intact but catalytically inactive GH76 mutant (GH76mut) was expressed 
replacing the two aspartic acid residues D136 D137 at the active site for alanine 136A 137A. 
Co-crystallization trials were set in the presence of mannosides with different length (35-40) 
and GH76mut. The D136A-D137A mutant in complex with tetramannoside 37 crystallized 
successfully and the structure was solved using a molecular replacement method using a WT 
structure as a search model. Figure 3.3 presents the crystal structure of GH76AWT (apo-form, 
resolution 2.0 Å) and Figure 3.4 shows the crystal structure of GH76mut with tetramannoside 37 
at the active site with a 1.9 Å resolution. Both images show a typical (/)6 fold, where six -
helices are forming a core covered by another layer of six -helices around them. A similar 
structural fold was present in other homologs of GH76 from gut microbiota resident 
Bacteroides thetaiotaomicron132 and the soil bacterium Bacillus circulans.136 In both apo-form 
and substrate-bound form, a total of 12 -helices and 6 -strands are present.  
The structural alignment and sequence alignment suggested that the catalytic residues 
Asp137 and Asp137 are conserved among the GH76 family. 




Figure 3.3 Cartoon representation of GH76AWT crystal structure showing (/)6 fold having 
the active site in the center (highlighted catalytic residues ASP136 and ASP137 in closer-view 
at right side panel).  
 
Figure 3.4 (A) 3D-Crystal structure of GH76Amut in complex with tetramannoside 37 shows in 
a ball-stick representation. (B) Surface-view representation of GH76Amut showing ligand 
pocket and catalytic residues mutated to Alanines (red). (C) Closer-view of active site revealing 
the distinct binding mode of tetramannoside 37. 
The ligand-bound form resulted in a RMSD of 0.228 Å, indicating no global change in the 
structure upon ligand binding. In the initial model, the electron density of tetramannoside 37 
was visible and it is enough for four mannose molecules to fit into the active site (Figure 3.4). 
The surface view representation shows the active site cavity with 37 adopting a very sharp bent 
in the middle to occupy the active site (Figure 3.4). The attempts to co-crystallize different 





 Recombinantly purified GH76AWT has -1,6-mannanase activity 
 The preliminary analysis by high-performance anion-exchange chromatography 
coupled with pulsed amperometric detection (HPAEC-PAD) showed that the GH76AWT 
purified from heterologous host is functional and has -1,6-mannanase activity. Yeast-mannan 
from Saccharomyces cerevisiae digested by this mannanase was hydrolyzed mainly into 
dimannoside 36 (Figure 3.5). The digested products were qualitatively analyzed on HPLC and 
identified by comparison with known synthetic oligosaccharides standard. Additionally, the 
presence of higher length mannan oligosaccharides in HPLC elution chromatogramm suggested 
an endo acting enzyme. For the next experiment, mannan-like oligosaccharides with -1,6-
linkages (36-40) were digested and analyzed by RP-HPLC. Different products with shorter 
lengths were identified (data from digestion of mannoside 40 is shown here as an example). 
When heptamannoside 40 was digested with GH76AWT, the digested products were identified 
as dimannoside 36 and pentamannoside 38 (Figure 3.6). As the length of digested products is 
different, we propose that GH76A is an endo-acting enzyme. As expected, the double amino 
acid inactive mutant GH76mut could not digest the yeast-mannan as well as the synthetic 
oligosaccharide 40 (Figure 3.5C, Figure 3.6C).  




Figure 3.5 HPAEC-PAD chromatogramms of a) Control experiment: yeast-mannan and buffer 
b) Digestion of yeast-mannan with GH76AWT. At 3.5 min dimannoside 35 was detected as 






Figure 3.6 HPAEC-PAD of a) Control experiment: heptamannoside 40 and buffer b) Digestion 
of heptamannoside 40 with GH76AWT. At 3.5 min was detected the dimannoside 35 along with 
pentamannoside 38 at 6.25 min as reaction products c) Digestion of heptamannoside 40 with 
GH76Amut- no reaction observed. 
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 AGA of linear and branched glucosides 
β-(1,3)-glucans (laminarin) derivatives 44-50 (Figure 3.7) with specific β-(1,6) and β-(1,4) 
substitution patterns were chosen as model substrates to determine the specificity of three 
different exo-glucanases obtained from marine sources with probable β-(1,3), β-(1,4), β-(1,6) 
glucanase activity. To synthesize the laminarin series, three different glucose BBs 41 – 43 and 
a traceless photocleavable linker 21 based on the o-nitrobenzyl scaffold were used (Figure 
3.7).114 This linker, upon photo-cleavage, reveals an oligosaccharide with a free reducing end 
to obtain fully natural glycans. 
Figure 3.7 AGA of β-(1,3)-glucans with specific β-(1,6) and β-(1,4) substitution patterns 44-
50 ranging from pentamer to decaglucoside using a traceless photocleavable linker 21. 
AGA of linear and branched β-(1,3)-glucans carrying an aminoalkyl spacer at the reducing 
end was reported before using glycosyl phosphate building blocks and a photolabile linker.137 
Convergent solution-phase syntheses of β-(1,3)-glucans were carachterized by low yields and 
aberrant α-linkage formation due to double-stereo differentiation effects as well as limitations 





Here, the core structure of laminarin structures was synthesized using BB 41 bearing Fmoc 
as a temporary protecting group for chain elongation at C-3 and Bz esters in the C2-position to 
ensure β-selectivity during glycosylation. The phosphate leaving group was selected since 
glycosyl phosphates provide the best coupling efficiencies, as previously described.12 AGA 
cycles consisting of four modules (Figure 3.7) were utilized as mentioned in section 3.3. For 
the glycosylation, only 4.0 equivalents of phosphate donor 41 were required for coupling to the 
resin upon activation with TMSOTf (from -30 °C to -10 °C). These conditions permitted the 
assembly of linear β-(1,3)-heptaglucose 44 in 30% yield.  
To obtain the mixed β-(1,3)-β-(1,4)-linked structures, an analogue of BB 41 bearing Fmoc 
as a temporary protecting group for chain elongation at C-4 (BB 42) was synthesized. The thiol 
leaving group was selected since it was previously reported for its use in AGA113 using 6.5 
equivalents of BB per cycle. Several β-(1,3)-β-(1,4)-glucans such as pentaglucoside 45 as well 
as octaglucosides 46 and 47 were prepared using BB 41 and 42 with an overall yield of 22, 9 
and 6% respectively (Table 3.2,). 
 Structures 48-50 are based on a β-(1,3) linear backbone with β-(1,6)-branches. The 
backbone was firstly built using the predefined sequence of glycosyl phosphates 41 and 43. 
Building block 43 contains a C-3 Fmoc-protected hydroxyl group and a Lev ester on the C-6 
hydroxyl. Upon completion of the backbone, selective removal of the levulinoyl ester allowed 
for the insertion of the β-(1,6)-branch. Module E (20% piperidine in DMF) was standardly used 
to remove Fmoc. However, in the presence of Lev, module E2 (20% Et3N in DMF) was 
employed, to avoid Lev migration. The methanolysis of base-labile protecting groups, as part 
of the global deprotection, was performed directly on the solid support and proved to be more 
effective than the more common solution phase methanolysis. The partially protected 
oligosaccharides were photocleaved from the resin and immediately debenzylated via 
hydrogenation using the Pd/C catalyst (60 psi in <1 h). 
  











Table 3.2 AGA of -(1,3)-glucans with specific β-(1,6) and β-(1,4) substitution patterns 44-50 
based on resin loading after AGA and two steps global deprotection.  
With this protocol, only a single purification with reverse-phase HPLC was needed to yield 
oligosaccharides 44 and 45 in 30% and 22% yields, respectively. Branched octasaccharides 48, 
49 and 50, as well as long linear structures 46 and 47 were isolated in lower quantities (6 – 
16%) because these glycans unexpectedly partially fragmented during hydrogenation. 
The application of these glucans as standards for determining the substrate specificities of 
the above-mentioned enzymes is still ongoing.  
 Conclusion 
Synthetic α-(1,6)-oligomannosides are valuable standards for determining the substrate 
specificity of the mannose-degrading enzymes of the class of mannanases, as shown here for 
GH67A. A detailed 3D structure of the active site of GH76A was obtained via X-ray diffraction 
of the co-crystallized synthetic tetramannoside with mutant mannanase GH76. The structure of 
the active is conserved among the GH76 family. Digestion of the synthetic mannosides with 
GH76A indicated that mannanase GH76A is acting as an α-(1,6) endo-enzyme. Furthermore, 
the synthesis of seven β-(1,3)-glucans with specific β-(1,6) and β-(1,4) substitution patterns as 
long as 10-mer was successfully enabled by using phosphate glycosyl donors together with 
TMSOTf as promoter in AGA. Two new traceless photocleavable linkers were tested and 
successfully afforded glycans with free reducing ends. Laminarin analogs will be tested to 





 General Materials and Methods 
 
All chemicals used were reagent grade and used as supplied unless otherwise noted. All 
building blocks used were purchased from GlycoUniverse, Germany. Automated syntheses 
were performed on a home-built synthesizer developed at the Max Planck Institute of Colloids 
and Interfaces.108 Merrifield resin LL (100-200 mesh, NovabiochemTM) was modified and used 
as solid support.105 Analytical thin-layer chromatography (TLC) was performed on Merck silica 
gel 60 F254 plates (0.25 mm). Compounds were visualized by UV irradiation or dipping the 
plate in a p-anisaldehyde (PAA) solution. Flash column chromatography was carried out by 
using forced flow of the indicated solvent on Fluka Kieselgel 60 M (0.04 – 0.063 mm). Analysis 
and purification by normal and reverse phase HPLC was performed using an Agilent 1200 
series. Products were lyophilized using a Christ Alpha 2-4 LD plus freeze dryer. 1H, 13C and 
HSQC NMR spectra were recorded on a Varian 400-MR (400 MHz), Varian 600-MR (600 
MHz), or Bruker Biospin AVANCE700 (700 MHz) spectrometer. Spectra were recorded in 
CDCl3 by using the solvent residual peak chemical shift as the internal standard (CDCl3: 7.26 
ppm 1H, 77.0 ppm 13C) or in D2O using the solvent as the internal standard in 
1H NMR (D2O: 
4.79 ppm 1H) and a D6-acetone spike as the internal standard in 13C NMR (acetone in D2O: 
30.89 ppm 13C) unless otherwise stated. High resolution mass spectra were obtained using a 
6210 ESI-TOF mass spectrometer (Agilent) and a MALDI-TOF AutoflexTM (Bruker). MALDI 
and ESI mass spectra were run on IonSpec Ultima instruments.  HPAEC‐PAD was performed 
in a Dionex ICS‐5000 system (Thermo Fischer Scientific Inc., Waltham, MA, USA) with a 
working  gold electrode and a pH (Ag/AgCl) reference electrode. 
 Solvents used for dissolving building block and preparing the activator, TMSOTf and 
capping solutions were taken from an anhydrous solvent system (jcmeyer-solvent systems). 
Other solvents used were HPLC grade. The building blocks were co-evaporated three times 
with toluene and dried 2 h under high vacuum before use. Activator, deprotection, acidic wash, 
capping and building block solutions were freshly prepared and kept under argon during the 
automation run. All yields of products obtained by AGA were calculated based on resin loading. 
Resin loading was determined by performing one glycosylation (Module C) with ten 
equivalents of building block followed by DBU promoted Fmoc-cleavage and determination of 
dibenzofulvene production by measuring its UV absorbance.  
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 Preparation of stock solution. 
 
• Building block: building block was dissolved in 1 mL dichloromethane (DCM).  
• Activator solution: 1.56 g of recrystallized NIS was dissolved in 60 mL of a 2:1 
mixture of anhydrous DCM and anhydrous dioxane. Then triflic acid (67 μL) was 
added. The solution is kept at 0 °C for the duration of the automation run. 
• Activator Solution 2: 0.9 mL of TMSOTf was added to 40 mL of CH2Cl2 
• Fmoc deprotection solution: A solution of 20% piperidine in dimethylformamide 
(DMF) (v/v) was prepared. 
• Fmoc Deprotection Solution 2: 20 mL of Et3N was added to 80 mL of anhydrous 
DMF 
• TMSOTf solution: Trimethylsilyl trifluoromethanesulfonate (TMSOTf) (0.9 mL) 
was added to DCM (90 mL). 
• Capping solution: A solution of 10% acetic anhydride (Ac2O) and 2% 
methanesulfunic acid (MsOH) in anhydrous DCM (v/v) was prepared. 
 
 Modules for automated synthesis 
 
  Module A: Resin Preparation for Synthesis (20 min) 
 
All automated syntheses were performed on 19 µmol scale. Resin was placed in the 
reaction vessel and swollen in DCM for 20 min at room temperature prior to synthesis. During 
this time, all reagent lines required for the synthesis were washed and primed. Before the first 
glycosylation, the resin was washed with the DMF, tetrahydrofuran (THF), and DCM (three 






 Module B: Acidic Wash with TMSOTf Solution (20 min) 
The resin was swollen in 2 mL DCM and the temperature of the reaction vessel was 
adjusted to -20 °C. Upon reaching the temperature, TMSOTf solution (1 mL) was added drop 
wise to the reaction vessel. After bubbling for 3 min, the acidic solution was drained and the 
resin was washed with 2 mL DCM for 25 s. 
 Module C: Thioglycoside Glycosylation (25  min) 
The building block solution (0.150 mmol of BB in 1 mL of DCM per glycosylation) was 
delivered to the reaction vessel. After the set temperature (T1) was reached, the reaction was 
started by drop wise addition of the activator solution (1.0 mL, excess). The glycosylation was 
performed by increasing the temperature to T2 for 20-60 min (depending on oligosaccharide 
length). After completion of the reaction, the solution is drained and the resin was washed with 
DCM, DCM:dioxane (1:2, 3 mL for 20 s) and DCM (twice, each with 2 mL for 25 s). The 
temperature of the reaction vessel is increased to 25 °C for the next module. 
  Module C2: Glycosylation with Glycosylphosphate (55 min) 
 The building block solution (0.08 mmol of BB in 1mL of DCM) was delivered to the reaction 
vessel. After initiation temperature (T1) was reached, Activator Solution 2  solution  (1 mL) 
was added dropwise to the reaction vessel. Incubation temperature (T2) was set and the 
incubation duration (t2) was adjusted depending on the BB. The values for building block  were 
shown in the table below. The solution was drained and the resin was washed with CH2Cl2, 
CH2Cl2/dioxane (1:2, 3 mL for 20 s) and CH2Cl2 (twice, each with 2 mL for 25 s). The 
temperature was increased to 25 C. 
 Module D: Capping (30 min) 
 The resin was washed with DMF (twice with 2 mL for 25 s) and the temperature of the 
reaction vessel was adjusted to 25 °C. Pyridine solution 2 mL (10% in DMF) was delivered into 
the reaction vessel. After 1 min, the reaction solution was drained and the resin washed with 
DCM (three times with 3 mL for 25 s). The capping solution 4 mL was delivered into the 
reaction vessel. After 20 min, the reaction solution was drained and the resin washed with DCM 
(three times with 3 mL for 25 s).  
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  Module E: Fmoc Deprotection (14 min) 
 The resin was washed with DMF (three times with 2 mL for 25 s) and the temperature of 
the reaction vessel was adjusted to 25 °C. Fmoc deprotection solution (2 mL) was delivered 
into the reaction vessel. After 5 min, the reaction solution was drained and the resin washed 
with DMF (three times with 3 mL for 25 s) and DCM (five times each with 2 mL for 25 s). The 
temperature of the reaction vessel is decreased to -20 °C for the next module. 
 Module E2: Fmoc Deprotection (14 min) 
 The resin was washed with DMF (three times with 2 mL for 25 s) and the temperature of 
the reaction vessel was adjusted to 25 °C. Fmoc deprotection solution 2  (2 mL 20% Et3N in 
DMF) was delivered into the reaction vessel. After 5 min, the reaction solution was drained, 
and the resin washed with DMF (three times with 3 mL for 25 s) and DCM (five times each 
with 2 mL for 25 s). The temperature of the reaction vessel is decreased to -20 °C for the next 
module. 
 
 Post-synthesizer Manipulations 
 
 Cleavage from Solid Support 
After automated synthesis, the oligosaccharides were cleaved from the solid support using 
a continuous-flow photo reactor. The Vapourtec E-Series UV-150 Photoreactor Flow 
Chemistry System with mercury lamp was employed. The resin, suspended in CH2Cl2, was 
loaded into a plastic syringe. The suspension was pumped using a syringe pump (PHD2000, 
Harvard Aparatus) at 1 mL/min through a 10 mL reactor, constructed of 1/8 inch o.d. FEP 
tubing. The temperature of the photoreactor was maintained at 20 C.108 
 Purification 
Crude products were analyzed and purified using analytical or preparative HPLC (Agilent 





Module A (YMC-Diol-300 column, 150 x 4.6 mm): flow rate of 1.0 mL/min with 20% 
EtOAc/Hexane as eluents [isocratic (5 min), linear gradient to 55% EtOAc (30 min), linear 
gradient to 100% EtOAc (5 min)]. 
Module B (YMC-Diol-300 column, 150 x 20 mm): flow rate of 4.6 mL/min with 20% 
EtOAc/Hexane as eluents [isocratic (5 min), linear gradient to 55% EtOAc (30 min), linear 
gradient to 100% EtOAc (5 min)]. 
Module C (Synergi Hydro RP18 column, 250 x 2.6 mm): flow rate of 0.7 mL/min with H2O 
(0.1% formic acid) as eluents [isocratic (5 min), linear gradient to 10% ACN (30 min), linear 
gradient to 100% ACN (5 min)]. 
Module D (Synergi Hydro RP18 column, 250 x 10 mm): flow rate of 3.7 mL/min with H2O 
(0.1% formic acid) as eluents [isocratic (5 min), linear gradient to 10% ACN (30 min), linear 
gradient to 100% ACN (5 min)]. 
Method E: (Hypercarb column, 150 x 4.6 mm) flow rate of 0.7 mL / min with H2O (0.1% 
formic acid) as eluents [isocratic (5 min), linear gradient to 30% ACN (30 min), linear gradient 
to 100% ACN (5 min)]. 
Method F: (Hypercarb column, 150 x 10 mm) flow rate of 1.3 mL / min with H2O (0.1% formic 
acid) as eluents [isocratic (5 min), linear gradient to 30% ACN (30 min), linear gradient to 
100% ACN (5 min)]. 
 
 Oligosaccharide deprotection 
 
Module G: Methanolysis 
The protected oligosaccharide was dissolved in MeOH:DCM (1.5 mL,1:1). NaOMe in 
MeOH (0.1 mL of 0.5M solution) was added to the solution and stirred at room temperature. 
After 12 h, the solution was neutralized with Amberlite IR-120 (H+ form) resin, filtered and 
concentrated in vacuo. The crude compound was used for hydrogenolysis without further 
purification.  
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Module H: Hydrogenolysis with Pd/C 
The crude compound obtained from Module G was dissolved in 2 mL of DCM:tBuOH:H2O 
(1:0.5:0.5) and Pd/C (10%) was added. The reaction was stirred in H2 bomb with 60 psi pressure 
for 16 hours. The reaction was filtered, washed with DCM, tBuOH and H2O. The filtrates were 
concentrated in vacuo.  
 AGA Synthesis of mannosides 
 Synthesis of α-(1,6) linear dimannoside (29) 
 
Cycles Module Conditions 
 A: Resin Preparation for Synthesis  
 
  2 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation 
D: Capping 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 30 min 
E: Fmoc Deprotection  
 
Cleavage from solid support as described in section 4.4.2 Photocleavage, followed by 
purification using preparative HPLC (Method B) afforded compound 29 (5 mg, 31% from resin 
28).  
Analytical data for 29: 1H NMR (600 MHz, Chloroform-d) δ 8.09 (ddt, J = 9.5, 8.3, 1.3 
Hz, 4H), 7.63 – 7.57 (m, 1H), 7.55 – 7.49 (m, 1H), 7.51 – 7.44 (m, 4H), 7.36 – 7.26 (m, 9H), 
7.29 – 7.23 (m, 5H), 7.26 – 7.21 (m, 1H), 7.23 – 7.16 (m, 3H), 7.15 – 7.08 (m, 3H), 5.72 (dd, J 
= 3.1, 1.9 Hz, 1H), 5.67 (dd, J = 3.3, 1.8 Hz, 1H), 5.04 (d, J = 1.9 Hz, 1H), 4.97 (d, J = 1.8 Hz, 
1H), 4.91 (d, J = 11.0 Hz, 1H), 4.87 (d, J = 11.1 Hz, 1H), 4.82 (d, J = 11.0 Hz, 1H), 4.72 (d, J 
= 11.5 Hz, 1H), 4.69 – 4.61 (m, 4H), 4.60 (s, 0H), 4.56 – 4.44 (m, 4H), 4.11 (ddd, J = 19.4, 9.2, 
3.2 Hz, 2H), 3.97 (t, J = 9.5 Hz, 1H), 3.95 – 3.88 (m, 2H), 3.88 – 3.82 (m, 1H), 3.82 – 3.77 (m, 





140.94, 138.46, 138.34, 138.03, 137.82, 136.28, 133.43, 133.41, 130.06, 130.00, 129.98, 
128.69, 128.65, 128.50, 128.48, 128.45, 128.29, 128.26, 128.09, 127.94, 127.86, 127.83, 
127.81, 127.76, 127.30, 98.01, 97.09, 78.75, 77.97, 77.37, 77.16, 76.95, 75.41, 75.35, 74.43, 
74.08, 72.26, 71.83, 71.47, 71.04, 69.30, 69.15, 68.93, 66.35, 65.23, 62.17. m/z (HRMS+) 
1053.408 [M + Na]+ (C62H62NaO14
+ requires m/z: 1053.403). 
 
Deprotection of 29 as described in Module G , followed by purification using preparative 
HPLC (Method F) afforded compound 35  as a mixture of α and β isomers (1.0 mg, 3.2 µmol, 
60% over two steps) 
 
RP-HPLC of 35 (ELSD trace, Method E, tR = 16.1 min) 
 
Analytical data for 35: 1H NMR (700 MHz, Deuterium Oxide) δ 8.59 (dd, J = 2.4, 1.2 Hz, 
1H), 5.30 (d, J = 2.3 Hz, 1H), 5.06 – 5.02 (m, 3H), 4.13 (qt, J = 4.6, 2.7 Hz, 3H), 4.11 – 4.06 
(m, 4H), 4.06 – 3.98 (m, 10H), 3.98 – 3.94 (m, 1H), 3.94 – 3.91 (m, 3H), 3.91 – 3.87 (m, 5H), 
3.87 – 3.76 (m, 10H), 3.75 – 3.67 (m, 1H), 3.67 – 3.64 (m, 1H). 13C NMR (176 MHz, D2O) δ 
99.93, 99.72, 94.31, 93.96, 74.43, 73.31, 72.84, 72.81, 71.29, 71.01, 70.79, 70.69, 70.58, 70.14, 
70.06, 69.38, 69.11, 68.77, 66.90, 66.86, 66.65, 66.01, 63.37, 61.08.  m/z (HRMS+) 365.1110 
[M + Na]+ (C12H22NaO11+ requires m/z: 365.1054). 
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 Synthesis of α-(1,6) linear trimannoside (30) 
 
 
Cycles Module Conditions 
 A: Resin Preparation for Synthesis  
 
3  
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation 
D: Capping 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 30 min 
E: Fmoc Deprotection  
 
Cleavage from solid support as described in section 4.4.2 Photocleavage, followed by 
purification using preparative HPLC (Method B) afforded compound 30 (10.5 mg, 37% from 
resin 28).  
Analytical data for 30: 1H NMR (600 MHz, Chloroform-d) δ 8.14 (dd, J = 6.8, 2.9 Hz, 2H), 
8.07 (ddd, J = 16.0, 8.2, 1.5 Hz, 4H), 7.53 – 7.42 (m, 8H), 7.34 – 7.26 (m, 8H), 7.26 – 7.21 (m, 
16H), 7.21 – 7.11 (m, 11H), 5.77 (dd, J = 3.2, 1.9 Hz, 1H), 5.72 (t, J = 2.5 Hz, 1H), 5.66 (dd, J 
= 3.3, 1.9 Hz, 1H), 5.03 (dd, J = 19.2, 1.9 Hz, 1H), 4.96 (d, J = 1.8 Hz, 1H), 4.89 – 4.85 (m, 
2H), 4.79 (dd, J = 15.9, 11.1 Hz, 2H), 4.69 (d, J = 10.8 Hz, 2H), 4.62 (s, 1H), 4.59 (d, J = 11.1 
Hz, 1H), 4.52 (dd, J = 11.5, 9.6 Hz, 3H), 4.48 – 4.38 (m, 4H), 4.14 – 3.99 (m, 4H), 3.96 – 3.89 
(m, 4H), 3.89 – 3.78 (m, 5H), 3.73 – 3.59 (m, 6H).   13C NMR (151 MHz, cdcl3) δ 165.89, 
165.78, 165.60, 140.97, 138.60, 138.46, 138.06, 136.25, 133.40, 130.11, 130.07, 130.03, 
129.99, 128.77, 128.70, 128.66, 128.64, 128.47, 128.45, 128.37, 128.30, 128.18, 128.15, 
127.82, 127.79, 127.74, 127.63, 127.29, 98.33, 98.14, 97.09, 78.84, 78.37, 77.98, 77.37, 77.16, 
76.95, 75.34, 74.43, 74.22, 73.99, 72.32, 71.85, 71.56, 71.43, 71.20, 71.00, 69.27, 69.21, 68.85, 








Deprotection of 30 as described in Module G , followed by purification using preparative 
HPLC (Method F) afforded compound 36  as a mixture of α and β isomers (2.0 mg, 6.3 µmol, 
40% over two steps) 
 
RP-HPLC of 36 (ELSD trace, Method E, tR = 18.5 min) 
 
Analytical data for 36:1H NMR (700 MHz, Deuterium Oxide) δ 5.18 (s, 1H), 4.92 (s, 2H), 
4.91 (s, 1H), 4.89 (s, 2H), 4.03 – 3.95 (m, 7H), 3.97 – 3.93 (m, 4H), 3.93 – 3.87 (m, 11H), 3.87 
– 3.83 (m, 17H), 3.82 – 3.79 (m, 5H), 3.79 – 3.76 (m, 5H), 3.77 – 3.74 (m, 7H), 3.74 – 3.71 (m, 
9H), 3.70 – 3.69 (m, 1H), 3.68 – 3.64 (m, 6H). 13C NMR (176 MHz, D2O) δ 100.01, 99.54, 
72.86, 70.94, 70.71, 70.12, 69.37, 69.13, 69.02, 68.76, 66.90, 66.80, 65.82, 63.37, 61.09. m/z 
(HRMS+) 527.1599 [M + Na]+ (C18H32NaO16
+ requires m/z: 527.1583). 
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 Synthesis of α-(1,6) linear tetramannoside (31) 
 
Cycles Module Conditions 
 A: Resin Preparation for Synthesis  
 
4  
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation 
D: Capping 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 30 min 
E: Fmoc Deprotection  
 
Cleavage from solid support as described in section 4.4.2 Photocleavage, followed by 
purification using preparative HPLC (Method B) afforded compound 31 (15.2 mg, 55% from 
resin 28).  
Analytical Data for 31: 1H-NMR (400 MHz, CDCl3) δ 8.19-8.14 (m, 4H), 8.10 (s, 3H), 
8.08 (d, J = 2.0 Hz, 2H), 8.06 (d, J = 1.5 Hz, 1H), 7.64 – 7.57 (m, 1H), 7.48 (ddd, J = 13.9, 6.9, 
4.7 Hz, 11H), 7.33 – 7.18 (m, 28H), 7.18 – 7.09 (m, 9H), 5.82 (dd, J = 3.1, 1.9 Hz, 1H), 5.80 
(dd, J = 3.1, 1.9 Hz, 1H), 5.77 – 5.70 (m, 1H), 5.68 (dd, J = 3.3, 1.8 Hz, 1H), 5.09 (d, J = 1.8 
Hz, 1H), 5.06 (d, J = 1.7 Hz, 1H), 5.03 (d, J = 1.8 Hz, 1H), 4.96 (d, J = 1.8 Hz, 1H), 4.90 (d, J 
= 2.1 Hz, 1H), 4.87 (t, J = 1.8 Hz, 1H), 4.83 (s, 1H), 4.81 (s, 1H), 4.78 (s, 1H), 4.69 (dd, J = 
14.5, 11.7 Hz, 2H), 4.63 (s, 2H), 4.59 (d, J = 11.1 Hz, 1H), 4.55-4.50 (m, 2H), 4.50 – 4.47 (m, 
1H), 4.45 (d, J = 2.5 Hz, 2H), 4.42 (s, 1H), 4.41 – 4.32 (m, 1H) ppm; 13C-NMR (100 MHz, 
CDCl3) δ 137.58, 133.36, 133.30, 129.92, 129.89, 129.85, 128.66, 128.57, 128.53, 128.52, 
128.38, 128.35, 128.32, 128.29, 128.22, 128.19, 128.06, 128.04, 127.72, 127.68, 127.64, 
127.42, 127.38, 127.33, 127.13, 98.36, 98.18, 98.09, 96.86, 78.66, 78.27, 78.22, 75.21, 75.12, 
74.21, 73.92, 73.81, 73.68, 72.10, 71.68, 71.38, 71.35, 71.19, 71.06, 70.92, 69.04, 68.96, 68.55, 
68.51, 68.39, 66.22, 65.85, 65.51, 65.03, 61.83. m/z (HRMS+) for C116H114O26Na [M+Na]
+ 





Deprotection of 31 as described in Module G , followed by purification using preparative 
HPLC (Method F) afforded compound 37  as a mixture of α and β isomers (2.0 mg, 5.0 µmol, 
40% over two steps) 
 
RP-HPLC of 37 (ELSD trace, Method E, tR = 19.3 min) 
 
Analytical data for 37: 1H NMR (400 MHz, Deuterium Oxide) δ 5.12 (d, J = 1.8 Hz, 2H), 
4.87 (s, 2H), 4.86 (s, 2H), 4.85 (d, J = 3.2 Hz, 10H), 3.99 – 3.92 (m, 13H), 3.89 (dq, J = 7.2, 
4.7, 4.3 Hz, 9H), 3.84 (d, J = 1.6 Hz, 3H), 3.81 (dt, J = 3.7, 1.7 Hz, 8H), 3.79 – 3.76 (m, 10H), 
3.76 – 3.72 (m, 7H), 3.71 – 3.67 (m, 11H), 3.65 (dd, J = 5.2, 1.5 Hz, 4H), 3.65 – 3.56 (m, 6H). 
13C NMR (101 MHz, D2O) δ 99.49, 99.41, 99.18, 99.14, 94.10, 93.77, 74.06, 73.11, 72.62, 
71.07, 70.71, 70.64, 70.58, 70.55, 70.41, 70.39, 70.37, 69.86, 69.81, 66.63, 66.53, 66.50, 66.46, 
66.33, 65.62, 65.48, 65.38, 60.83. m/z (HRMS+) 689.2140 [M+Na]+ (C24H42NaO21+ requires 
m/z: 689.2111). 
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 Synthesis of α-(1,6) linear pentamannoside (32) 
 
 
Cycles Module Conditions 
 A: Resin Preparation for Synthesis  
 
5 
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation 
D: Capping 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 30 min 
E: Fmoc Deprotection  
 
Cleavage from solid support as described in section 4.4.2 Photocleavage, followed by 
purification using preparative HPLC (Method B) afforded compound 32 (12 mg, 35% from 
resin 28).  
Analytical data for 32: 1H NMR (600 MHz, Chloroform-d) δ 8.14 (q, J = 5.0, 4.5 Hz, 5H), 
8.11 – 8.05 (m, 5H), 7.48 (q, J = 3.2, 2.7 Hz, 11H), 7.44 (t, J = 8.5 Hz, 5H), 7.34 – 7.23 (m, 
10H), 7.25 – 7.03 (m, 43H), 5.82 – 5.72 (m, 4H), 5.08 – 5.00 (m, 4H), 4.91 – 4.74 (m, 11H), 
4.68 – 4.60 (m, 4H), 4.43 (dddd, J = 46.7, 42.8, 23.5, 11.7 Hz, 13H), 4.16 (d, J = 3.9 Hz, 2H), 
4.13 – 3.77 (m, 14H), 3.72 (ddd, J = 34.6, 14.2, 7.5 Hz, 4H), 3.61 (t, J = 10.1 Hz, 2H), 3.49 (dd, 
J = 11.3, 5.8 Hz, 2H). 13C NMR (151 MHz, cdcl3) δ 165.69, 138.64, 133.41, 130.02, 128.78, 
128.62, 128.47, 128.43, 128.38, 128.30, 127.83, 127.51, 127.36, 127.26, 98.35, 78.83, 78.43, 
77.37, 77.16, 76.95, 75.19, 74.42, 74.15, 73.93, 73.49, 71.85, 71.54, 71.30, 71.17, 70.20, 69.22, 
68.62, 65.95, 65.17. m/z (HRMS+) 2392.930 [M + Na]+ (C143H140NaO32







Deprotection of 32 as described in Module G , followed by purification using preparative 
HPLC (Method F) afforded compound 38  as a mixture of α and β isomers (2.4 mg, 2.9 µmol, 
60% over two steps). 
 
RP-HPLC of 38 (ELSD trace, Method E, tR = 19.8 min) 
 
Analytical data for 38: 1H NMR (600 MHz, Deuterium Oxide) δ 5.18 (s, 1H), 4.94 – 4.89 
(m, 8H), 4.01 (q, J = 4.2, 3.3 Hz, 8H), 3.96 (dq, J = 10.2, 6.4, 5.5 Hz, 11H), 3.92 (d, J = 2.0 Hz, 
1H), 3.90 (d, J = 1.9 Hz, 1H), 3.91 – 3.82 (m, 16H), 3.81 (s, 2H), 3.79 (d, J = 5.8 Hz, 3H), 3.76 
(d, J = 7.9 Hz, 3H), 3.73 (d, J = 10.0 Hz, 7H), 3.67 (s, 1H). 13C NMR (151 MHz, d2o) δ 99.51, 
99.45, 99.26, 99.23, 99.20, 94.12, 93.78, 81.66, 74.09, 73.13, 72.64, 71.10, 70.74, 70.72, 70.68, 
70.64, 70.62, 70.60, 70.57, 70.46, 70.44, 70.42, 69.90, 69.86, 69.83, 69.80, 66.67, 66.59, 66.55, 
66.54, 66.52, 66.39, 65.67, 65.57, 65.53, 65.45, 60.86.  m/z (HRMS+) 851.2644 [M + Na]+ 
(C30H52NaO26
+ requires m/z: 851.2639). 
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 Synthesis of α-(1,6) linear hexamannoside (33) 
 
Cycles Module Conditions 
 A: Resin Preparation for Synthesis  
 
6  
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation 
D: Capping 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 30 min 
E: Fmoc Deprotection  
 
Cleavage from solid support as described in section 4.4.2 Photocleavage, followed by 
purification using preparative HPLC (Method B) afforded compound 33 (15 mg, 38% from 
resin 28).  
Analytical data for 33: 1H NMR (600 MHz, Chloroform-d) δ 8.18 – 8.13 (m, 8H), 8.08 (dd, 
J = 8.0, 5.8 Hz, 5H), 7.58 (t, J = 7.4 Hz, 1H), 7.53 – 7.42 (m, 19H), 7.33 – 7.27 (m, 10H), 7.26 
– 7.22 (m, 6H), 7.22 – 7.14 (m, 27H), 7.13 – 7.08 (m, 11H), 5.84 – 5.74 (m, 6H), 5.67 (t, J = 
2.6 Hz, 1H), 5.10 – 5.01 (m, 6H), 4.97 – 4.94 (m, 1H), 4.92 – 4.84 (m, 7H), 4.84 – 4.75 (m, 
7H), 4.69 (dd, J = 30.6, 11.6 Hz, 3H), 4.64 – 4.57 (m, 4H), 4.57 – 4.32 (m, 15H), 4.16 – 3.85 
(m, 18H), 3.85 – 3.68 (m, 7H), 3.68 – 3.56 (m, 6H), 3.56 – 3.51 (m, 2H), 3.46 (dd, J = 11.1, 5.4 
Hz, 2H). 13C NMR (151 MHz, cdcl3) δ 165.87, 165.76, 165.68, 165.66, 165.56, 140.98, 138.67, 
138.64, 138.61, 138.44, 138.35, 138.06, 137.77, 137.73, 137.72, 137.69, 137.67, 136.17, 
133.44, 133.40, 130.13, 130.11, 130.04, 130.01, 129.97, 128.78, 128.69, 128.63, 128.49, 
128.46, 128.43, 128.38, 128.37, 128.31, 128.29, 128.27, 128.18, 128.15, 127.83, 127.81, 
127.79, 127.77, 127.75, 127.57, 127.52, 127.49, 127.48, 127.40, 127.32, 127.26, 127.24, 98.63, 
98.61, 98.54, 98.33, 98.28, 97.07, 78.81, 78.41, 78.38, 78.34, 78.31, 77.83, 77.37, 77.16, 76.95, 
75.32, 75.25, 75.23, 75.16, 75.14, 74.36, 74.10, 73.98, 73.91, 73.85, 72.25, 71.83, 71.53, 71.50, 
71.46, 71.44, 71.34, 71.25, 71.17, 71.13, 71.07, 69.20, 69.15, 68.72, 68.61, 68.55, 68.53, 66.28, 







Deprotection of 33 as described in Module G , followed by purification using preparative 
HPLC (Method F) afforded compound 39  as a mixture of α and β isomers (3  mg, 3.6 µmol, 
58% over two steps). 
 
 RP-HPLC of 39 (ELSD trace, Method E tR = 20.5 min) 
 
Analytical data for 39: 1H NMR (700 MHz, Deuterium Oxide) δ 5.31 (s, 1H), 5.07 – 5.02 
(m, 10H), 4.15 – 4.12 (m, 10H), 4.12 – 4.05 (m, 13H), 4.05 – 4.00 (m, 3H), 4.00 – 3.95 (m, 
21H), 3.95 – 3.90 (m, 6H), 3.92 – 3.88 (m, 3H), 3.90 – 3.84 (m, 10H), 3.83 – 3.77 (m, 4H). 13C 
NMR (176 MHz, D2O) δ 99.73, 99.67, 99.46, 94.32, 93.98, 74.34, 73.35, 72.86, 71.31, 70.97, 
70.92, 70.90, 70.86, 70.71, 70.64, 70.13, 70.09, 70.07, 69.36, 66.92, 66.86, 66.80, 66.65, 65.95, 
65.86, 65.81, 65.75, 65.73, 63.37, 61.09, 55.59.m/z (HRMS+) 1013.318 [M + Na]+ 
(C36H62NaO31+ requires m/z: 1013.316). 
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 Synthesis of α-(1,6) linear heptamannoside (34) 
 
Cycles Module Conditions 
 A: Resin Preparation for Synthesis  
 
7  
B: Acidic Wash with TMSOTf Solution  
C: Thioglycoside Glycosylation 
D: Capping 
BB1 6.5 eq, -20 °C for 5 min, 0 °C for 30 min 
E: Fmoc Deprotection  
 
Cleavage from solid support as described in section 4.4.2 Photocleavage, followed by 
purification using preparative HPLC (Method B) afforded compound 34 (29 mg, 63% from 
resin 28).  
Analytical data for 34: 1H NMR (600 MHz, Chloroform-d) δ 8.16 (ddt, J = 7.9, 4.9, 3.0 
Hz, 9H), 8.08 (ddt, J = 8.0, 6.0, 2.5 Hz, 4H), 7.62 – 7.55 (m, 1H), 7.48 (dqd, J = 15.3, 7.6, 5.0 
Hz, 19H), 7.34 – 7.03 (m, 55H), 5.82 (dq, J = 7.5, 2.5 Hz, 4H), 5.80 – 5.77 (m, 1H), 5.76 (t, J 
= 2.5 Hz, 1H), 5.67 (dd, J = 3.3, 1.8 Hz, 1H), 5.10 – 5.01 (m, 6H), 4.95 (d, J = 1.8 Hz, 1H), 
4.92 – 4.69 (m, 15H), 4.69 – 4.57 (m, 4H), 4.57 – 4.31 (m, 15H), 4.16 – 3.86 (m, 17H), 3.85 – 
3.70 (m, 5H), 3.73 – 3.62 (m, 5H), 3.64 – 3.50 (m, 5H), 3.46 (td, J = 11.8, 1.9 Hz, 3H). 13C 
NMR (151 MHz, cdcl3) δ 165.87, 165.76, 165.68, 165.56, 140.98, 138.66, 138.61, 138.59, 
138.45, 138.35, 138.06, 137.77, 137.74, 137.71, 137.69, 137.66, 136.17, 133.44, 133.39, 
130.13, 130.11, 130.05, 130.00, 129.97, 128.79, 128.77, 128.69, 128.63, 128.62, 128.49, 
128.47, 128.43, 128.38, 128.32, 128.29, 128.26, 128.18, 128.15, 127.83, 127.81, 127.79, 
127.77, 127.75, 127.58, 127.51, 127.49, 127.43, 127.38, 127.29, 127.26, 127.24, 98.64, 98.55, 
98.33, 98.29, 97.07, 78.81, 78.40, 78.38, 78.35, 78.31, 77.83, 77.37, 77.16, 76.95, 75.32, 75.26, 
75.23, 75.17, 75.13, 74.36, 74.10, 73.98, 73.89, 73.85, 72.25, 71.83, 71.53, 71.49, 71.45, 71.34, 
71.24, 71.18, 71.13, 71.07, 69.20, 69.15, 68.71, 68.61, 68.52, 66.28, 65.88, 65.59, 65.13, 61.97. 





Deprotection of 34 as described in Module G , followed by purification using preparative 
HPLC (Method F) afforded compound 40  as a mixture of α and β isomers (2.8  mg, 3.3 µmol, 
50% over two steps). 
 
RP-HPLC of 40 (ELSD trace, Method E tR = 21.6 min) 
 
Analytical data for 40: 1H NMR (700 MHz, Deuterium Oxide) δ 5.20 – 5.14 (m, 2H), 4.94 
– 4.90 (m, 14H), 4.03 – 3.99 (m, 21H), 4.00 – 3.93 (m, 28H), 3.93 – 3.84 (m, 35H), 3.85 – 3.74 
(m, 27H), 3.73 (t, J = 10.0 Hz, 21H), 3.69 – 3.63 (m, 6H). 13C NMR (176 MHz, D2O) δ 99.57, 
99.50, 99.29, 99.27, 99.25, 94.18, 93.84, 74.15, 73.19, 72.69, 71.15, 70.80, 70.74, 70.69, 70.66, 
70.51, 70.48, 69.95, 69.91, 69.88, 69.85, 66.72, 66.63, 66.60, 66.58, 66.56, 66.43, 65.72, 65.61, 
65.58, 65.49, 60.91.  m/z m/z (HRMS+) 1175,365 [M + Na]+ (C42H72NaO36
+ requires 1175,369). 
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 AGA synthesis of glucosides 
 Synthesis of β-(1,3) linear heptaglucoside (44) 
 
Automation sequence:  
Cycles Module Conditions 
 A: Resin Preparation for Synthesis  
 
7  
B: Acidic Wash with TMSOTf Solution  
C: Phosphate Glycosylation 
D: Capping 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
 
Post-Automation: Module G – Methanolysis, then Photocleavage, then Module H – 
Hydrogenation. The crude unprotected oligosaccharide was purified using reverse-phase 
preparative HPLC (Method D) to afford compound 44 (5.9 mg, 30%). 
Analytical Data for 44: 1H-NMR (600 MHz, D2O, both isomers) δ 5.10 (d, J = 3.7 Hz, 1H), 
4.67 – 4.65 (m, 5H), 4.63 – 4.60 (m, 3H), 4.54 (d, J = 8.0 Hz, 1H), 3.80 (d, J = 2.0 Hz, 6H), 
3.79 – 3.76 (m, 7H), 3.76 – 3.71 (m, 2H), 3.70 – 3.67 (m, 1H), 3.67 – 3.64 (m, 9H), 3.63 – 3.56 
(m, 9H), 3.44 – 3.40 (m, 8H), 3.40 – 3.34 (m, 14H), 3.32 – 3.25 (m, 3H), 3.22 (dd, J = 9.4, 7.9 
Hz, 2H) ppm; 13C-NMR (150 MHz, D2O) δ 102.74, 102.57, 102.46, 102.44, 95.61, 91.95, 
84.41, 84.16, 83.99, 82.18, 75.93, 75.55, 75.51, 75.48, 73.77, 73.38, 73.23, 73.17, 71.16, 70.99, 
69.50, 68.05, 68.01, 60.60, 60.46 ppm. m/z (HRMS+) for C42H72O36Na [M+Na]
+ calcd. 









RP-HPLC of 44 (ELSD trace, Method C, tR= 31.2 min) 
 
 Synthesis of mix β-(1,3)  and β-(1,4) pentaglucoside (45) 
 
Automation sequence:  
Cycles Module Conditions 
 A: Resin Preparation for Synthesis  
 
B: Acidic Wash with TMSOTf Solution  
C: Phosphate Glycosylation 
D: Capping 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
 
  
B: Acidic Wash with TMSOTf Solution  
C: 2x Thioglycoside Glycosylation 
D: Capping 
BB42 6.5 eq, -20 °C for 5 min, 0 °C for 20 min 





B: Acidic Wash with TMSOTf Solution  
C: 2x Phosphate Glycosylation 
D: Capping 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
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Post-Automation: Module G – Methanolysis, then Photocleavage, then Module H – 
Hydrogenation. The crude unprotected oligosaccharide was purified using reverse-phase 
preparative HPLC (Method D) to afford compound 45 (2.6 mg, 22%). 
Analytical Data for 45: 1H-NMR (700 MHz, D2O, both isomers) δ 5.16 (d, J = 3.7 Hz, 1H), 
4.73 – 4.65 (m, 2H), 4.59 (dd, J = 8.1, 1.6 Hz, 1H), 4.46 (d, J = 8.0 Hz, 2H), 3.92 (d, J = 2.2 
Hz, 1H), 3.91 – 3.89 (m, 2H), 3.86 – 3.85 (m, 4H), 3.85 – 3.83 (m, 6H), 3.82 – 3.77 (m, 1H), 
3.76 – 3.72 (m, 2H), 3.69 (dd, J = 8.3, 3.2 Hz, 2H), 3.65 (ddd, J = 16.3, 9.8, 4.0 Hz, 4H), 3.59 
(dd, J = 6.5, 2.7 Hz, 4H), 3.57 – 3.53 (m, 4H), 3.49 – 3.45 (m, 3H), 3.45 – 3.42 (m, 8H), 3.40 
(dd, J = 9.1, 6.9 Hz, 1H), 3.37 (d, J = 8.2 Hz, 1H), 3.34 (s, 1H), 3.30 – 3.25 (m, 2H) ppm; 13C-
NMR (176 MHz, D2O) δ 102.81, 102.68, 102.59, 102.48, 102.35, 95.69, 84.50, 84.22, 83.77, 
82.24, 78.54, 76.01, 75.61, 75.57, 75.56, 74.85, 74.15, 74.13, 73.82, 73.46, 73.23, 73.05, 71.04, 
69.58, 68.13, 68.08, 67.97, 60.70, 60.68, 60.56, 60.00 ppm. m/z (HRMS+) for C30H52O26Na 
[M+Na]+ calcd. 851.2639, found: 851.2628. 
RP-HPLC of 45 (ELSD trace, Method C, tR= 25.8 min) 
 


















 Synthesis of mix β-(1,3)  and β-(1,4) octaglucoside (46) 
 
Automation sequence:  
Cycles Module Conditions 
 A: Resin Preparation for Synthesis  
 
B: Acidic Wash with TMSOTf Solution  
C: Phosphate Glycosylation 
D: Capping 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
 
  
B: Acidic Wash with TMSOTf Solution  
C: 2x Thioglycoside Glycosylation 
D: Capping 
BB42 6.5 eq, -20 °C for 5 min, 0 °C for 20 min 





B: Acidic Wash with TMSOTf Solution  
C: 2x Phosphate Glycosylation 
D: Capping 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
 
Post-Automation: Module G – Methanolysis, then Photocleavage, then Module H – 
Hydrogenation. The crude unprotected oligosaccharide was purified using reverse-phase 
preparative HPLC (Method D) to afford compound 46 
Analytical Data for 46: 1H-NMR (600 MHz, D2O, both isomers) δ 5.11 (d, J = 3.7 Hz, 1H), 
4.63 – 4.67 (m, 6H), 4.65 – 4.60 (m, 3H), 4.54 (d, J = 8.0 Hz, 1H), 3.80 (d, J = 2.0 Hz, 6H), 
3.79 – 3.76 (m, 7H), 3.77 – 3.72 (m, 2H), 3.67 – 3.64 (m, 9H), 3.63 – 3.56 (m, 9H), 3.44 – 3.40 
(m, 9H), 3.40 – 3.34 (m, 16H), 3.32 – 3.25 (m, 3H), 3.22 (m, 2H) ppm; 13C-NMR (150 MHz, 
D2O) δ 102.74, 102.57, 102.46, 102.44, 95.61, 91.95, 84.41, 84, 12, 84.16, 83.99, 82.18, 75.93, 
75.55, 75.53, 75.48, 75,45, 73.80, 73.38, 73.23, 73.17, 71.16, 70.99, 69.50, 68.05, 68,03, 68.01, 
60.60, 60.45 ppm. m/z (HRMS+) for C48H82O41Na [M+Na]
+ calcd. 1337.422, found: 1337.421. 
 




RP-HPLC of 46 (ELSD trace, Method C, tR= 36.6) 
 
 Synthesis of mix β-(1,3)  and β-(1,4) decaglucoside (47) 
 
Automation sequence:  
Cycles Module Conditions 
 A: Resin Preparation for Synthesis  
 
2 
B: Acidic Wash with TMSOTf Solution  
C: Phosphate Glycosylation 
D: Capping 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
 
  
B: Acidic Wash with TMSOTf Solution  
C: 2x Thioglycoside Glycosylation 
D: Capping 
BB42 6.5 eq, -20 °C for 5 min, 0 °C for 20 min 





B: Acidic Wash with TMSOTf Solution  
C: 2x Phosphate Glycosylation 
D: Capping 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
 


















Post-Automation: Module G – Methanolysis, then Photocleavage, then Module H – 
Hydrogenation. The crude unprotected oligosaccharide was purified using reverse-phase 
preparative HPLC (Method D) to afford compound 47 
Analytical Data for 47: 1H-NMR (600 MHz, D2O, both isomers) δ 5.11 (d, J = 3.7 Hz, 1H), 
4.63 – 4.67 (m, 6H), 4.65 – 4.60 (m, 3H), 4.54 (d, J = 8.0 Hz, 1H), 3.80 (d, J = 2.0 Hz, 6H), 
3.79 – 3.76 (m, 9H), 3.76 – 3.73 (m, 2H), 3.68 – 3.63 (m, 12H), 3.62 – 3.56 (m, 11H), 3.45 – 
3.40 (m, 11H), 3.40 – 3.33 (m, 20H), 3.32 – 3.25 (m, 1H), 3.22 (m, 2H) ppm; ppm. m/z 
(HRMS+) for C60H102NaO51
+ [M+Na]+ calcd. 1661.528, found: 1661.533. 
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 Synthesis of mix β-(1,3)  and β-(1,6) heptaglucoside (48) 
 
Automation sequence:  
Cycles Module Conditions 
 A: Resin Preparation for Synthesis  
3 
B: Acidic Wash with TMSOTf Solution  
C: Phosphate Glycosylation 
D: Capping 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
 
  
B: Acidic Wash with TMSOTf Solution  
C: 2x Phosphate Glycosylation 
D: Capping 
BB43 4 eq, -30 °C for 10 min, -10 °C for 40 min 




B: Acidic Wash with TMSOTf Solution  
C: 2x Phosphate Glycosylation 
D: Capping 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
 D: Capping  




B: Acidic Wash with TMSOTf Solution  
C: 2x Phosphate Glycosylation 
D: Capping 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
 
Post-Automation: Module G – Methanolysis, then Photocleavage, then Module H – 
Hydrogenation. The crude unprotected oligosaccharide was purified using reverse-phase 
preparative HPLC (Method D) to afford compound. 
Analytical Data for 48: 1H-NMR (700 MHz, D2O, both isomers) δ 5.14 (d, J = 3.7 Hz, 1H), 
4.75 – 4.68 (m, 6H), 4.57 (d, J = 8.1 Hz, 1H), 4.49 (d, J = 8.0 Hz, 2H), 4.45 (d, J = 7.9 Hz, 2H), 
4.14 (m, 5H), 3.86 – 3.82 (m, 12H), 3.81 – 3.76 (m, 2H), 3.75 – 3.68 (m, 7H), 3.67 – 3.62 (m, 





4H) ppm; 13C-NMR (176 MHz, D2O) δ 102.93, 102.81, 102.64, 102.55, 102.52, 95.69, 92.03,  
84.49, 84.24, 84.14, 83.90, 76.11, 75.94, 75.62, 75.58, 75.53, 74.93, 74.58, 73.84, 73.46, 73.33 
73.20, 73.18, 73.07, 71.46, 71.07, 69.64, 69.55, 69.42, 68.62, 68.15, 68.13, 68.09, 60.54 ppm. 
m/z (HRMS+) for C42H72NaO36 [M+Na]
+ calcd. 1175.991, found: 1175.997. 
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 Synthesis of mix β-(1,3)  and β-(1,6) octaglucoside (49) 
 
Automation sequence:  
Cycles Module Conditions 







B: Acidic Wash with TMSOTf Solution  
C: 2x Phosphate Glycosylation 
D: Capping 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
B: Acidic Wash with TMSOTf Solution  
C: 2x Phosphate Glycosylation 
D: Capping 
BB43 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
 B: Acidic Wash with TMSOTf Solution  
C: 2x Phosphate Glycosylation 
D: Capping 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
 F– 2x Lev Deprotection  
 C: 6x Phosphate Glycosylation 
 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
 
Post-Automation: Module G – Methanolysis, then Photocleavage, then Module H – 
Hydrogenation. The crude unprotected oligosaccharide was purified using reverse-phase 
preparative HPLC (Method D) to afford compound 49 (1.7 mg, 8% from resin 5). 
Analytical Data for 49: 1H-NMR (700 MHz, D2O, both isomers) δ 5.15 (d, J = 3.7 Hz, 1H), 
4.75 – 4.64 (m, 6H), 4.59 (d, J = 8.1 Hz, 1H), 4.47 (d, J = 8.0 Hz, 2H), 4.43 (d, J = 7.9 Hz, 2H), 
4.14 (dd, J = 18.1, 11.5 Hz, 5H), 3.86 – 3.82 (m, 14H), 3.81 – 3.76 (m, 2H), 3.75 – 3.68 (m, 
9H), 3.68 – 3.60 (m, 13H), 3.55 – 3.36 (m, 32H), 3.35 – 3.31 (m, 4H), 3.28 (t, J = 8.7 Hz, 2H), 
3.24 (t, J = 8.6 Hz, 4H) ppm; 13C-NMR (176 MHz, D2O) δ 102.95, 102.90, 102.81, 102.64, 





75.64, 75.62, 75.58, 75.56, 75.52, 74.93, 74.58, 73.84, 73.46, 73.33, 73.30, 73.26, 73.22, 73.14, 
73.09, 71.23, 71.07, 69.64, 69.58, 69.42, 68.98, 68.62, 68.15, 68.13, 68.09, 60.70, 60.54 ppm. 
m/z (HRMS+) for C48H82O41Na [M+Na]
+ calcd. 1337.4224, found: 1337.4276. 
Repurified RP-HPLC of 49 (ELSD trace, Method C, tR= 33.7 min) 
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 Synthesis of mix β-(1,3)  and β-(1,6) octaglucoside (50) 
 
Automation sequence:  
Cycles Module Conditions 
 A: Resin Preparation for Synthesis  
3 
B: Acidic Wash with TMSOTf Solution  
C: Phosphate Glycosylation 
D: Capping 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
 
  
B: Acidic Wash with TMSOTf Solution  
C: 2x Phosphate Glycosylation 
D: Capping 
BB43 4 eq, -30 °C for 10 min, -10 °C for 40 min 




B: Acidic Wash with TMSOTf Solution  
C: 2x Phosphate Glycosylation 
D: Capping 
BB41 4 eq, -30 °C for 10 min, -10 °C for 40 min 
E: Fmoc Deprotection  
 D: Capping  




B: Acidic Wash with TMSOTf Solution  
C: 2x Phosphate Glycosylation 
D: Capping 
BB43 4 eq, -30 °C for 10 min, -10 °C for 40 min 
2x Lev Deprotection  
 E: Fmoc Deprotection  
 
Post-Automation: Module G – Methanolysis, then Photocleavage, then Module H – 
Hydrogenation. The crude unprotected oligosaccharide was purified using reverse-phase 
preparative HPLC (Method D) to afford compound 50 (3.5 mg, 16% from resin 5). 
Analytical Data for 50: 1H-NMR (600 MHz, D2O, both isomers) δ 5.11 (d, J = 3.7 Hz, 1H), 





4.11 – 4.07 (m, 5H), 3.81 – 3.74 (m, 17H), 3.70 – 3.54 (m, 26H), 3.50 – 3.34 (m, 32H), 3.30 – 
3.16 (m, 14H) ppm; 13C-NMR (150 MHz, D2O) δ 102.74, 102.72, 102.52, 102.43, 95.61, 91.91, 
85.14, 84.63, 84.17, 83.75, 82.99, 75.93, 75.80, 75.53, 75.48, 75.45, 74.45, 74.38, 73.53, 73.38, 
73.18, 73.14, 73.09, 72.99, 71.08, 70.75, 69.51, 68.67, 68.17, 68.15, 68.09, 68.06, 67.98, 60.63, 
60.47 ppm. m/z (HRMS+) for C48H82O41Na [M+Na]
+ calcd. 1337.4224, found: 1337.4276. 
RP-HPLC of 50 (ELSD trace, Method C, tR= 33.5 min) 
 
 Functional characterization of GH76  
 Crystallization and structure determination GH76AWT and GH76Amut 
For crystallization of GH76AWT, 52 mg/mL concentration was used for setting up initial 
crystallization trial in three well crystallization plates using commercial crystallization screens. 
The plates were incubated at 16 °C. Initial hits were observed within 2-3 days of setting up the 
crystallization trials. The diffraction quality crystals were obtained using 0.2 M Magnesium 
chloride hexahydrate, 0.1 M Sodium acetate pH 5.0 and 20 % PEG 6000. Diffraction data was 
collected on beamline P14 at EMBL, DESY (Hamburg). A total of 3600 images were obtained. 
Each image was exposed for 0.1 seconds with 0.1° oscillation. Data were processed using 
XDS136 and scaled using SCALA.138 The structure was solved at 2 Å resolution using molecular 
replacement by searching Lin0763 protein from Listeria innocua (PDB ID 3K7X) as search 
model in PHASER,139 respectively. For automatic model building, ARP/wARP140 server was 
used. The initial model was refined using PHENIX.REFINE141 and iterative rounds of the 
manual model building were carried out using COOT.142 The final R/Rfree of GH76A
WT 
structure is 18/22. There were no Ramachandran outliers in the build models.  
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For mutant, 5 mg/mL protein concentration was used to setup co-crystallization trays 
with 0.5 mg/mL of mannan-oligosaccharides in three well crystallization plates using 
commercial crystallization screens. The crystals were appeared after 2 months in 1.6 M tri-
sodium citrate. Diffraction data was collected on beamline P11 at DESY (Hamburg). A total of 
3600 images were obtained. Each image was exposed for 0.1 seconds with 0.1° oscillation. 
Data were processed using iMOSFLM143 and scaled using SCALA. The structure was solved 
at 1.9 Å resolution using molecular replacement by searching GH76AWT as search model in 
PHASER, respectively. For automatic model building, phenix.autobuild144 was used. The initial 
model was refined using PHENIX.REFINE and iterative rounds of the manual model building 
were carried out using COOT. The ligand mannotetrose was fitted using COOT and ligand 
refinement was performed in REFMAC5.145 The final R/Rfree of GH76A
mut structure is 13/19. 
There were no Ramachandran outliers in the build models. Both WT and mutant protein 
structures were submitted to Protein Data Bank (PDB) and deposited as PDB ID: 6SHD and 
6SHM, respectively. 
 Enzymatic digestion 
10 g of protein and 300 g of oligosaccharide were mixed and incubated at 37 C 
overnight. For yeast mannan, the incubation time was 30 min. The enzymatic reaction was 
stopped by heating at 95 C for 10 min. The reaction mixture was filtered through 0.2 m 
syringe filter and diluted 100 times with Milli-Q water. 100 L of the diluted reaction mixture 
was injected to the HPLC. The individual mannosides 35-40 (25 L) were injected in three 
different concentration as standards and their retention time were recorded.  
 HPAEC‐PAD Analysis 
Substrate digestion was analysed employing HPAEC‐PAD with a Dionex CarboPac 
PA100 analytical column (2 × 250 mm). Using a binary pump, the flow rate was adjusted to 1 
mL/min, starting from 100% Eluent A (100 mM NaOH in water) to 50% Eluent B (166mM 
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